ImmunoPrecise Antibodies (IPA) 40-F10 Jul 232023 FY Annual report (Canada)Financial data

Company Profile

Cover Page

Cover Page	12 Months Ended
Cover Page	Apr. 30, 2023 shares
Document Information [Line Items]
Document Type	40-F
Amendment Flag	false
Document Period End Date	Apr. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	IMMUNOPRECISE ANTIBODIES LTD.
Entity Central Index Key	0001715925
Entity File Number	001-39530
Entity Tax Identification Number	98-1508109
Current Fiscal Year End Date	--04-30
Entity Incorporation, State or Country Code	A1
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, Address Line One	3204-4464 Markham Street
Entity Address, City or Town	Victoria
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V8Z 7X8
City Area Code	250
Local Phone Number	483-0308
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IPA
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	25,050,260
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Entity Primary SIC Number	8731
Document Annual Report	true
Document Registration Statement	false
Annual Information Form	true
Audited Annual Financial Statements	true
Auditor Name	GRANT THORNTON LLP
Auditor Firm ID	248
Auditor Location	Houston, Texas
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	ImmunoPrecise Antibodies (USA), Ltd.
Entity Address, Address Line One	4837 Amber Valley Parkway Suite 11
Entity Address, City or Town	Fargo
Entity Address, State or Province	ND
Entity Address, Postal Zip Code	58104
City Area Code	701
Local Phone Number	353-0022

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Current assets
Cash	$ 8,280	$ 29,965
Amounts receivable, net	3,247	2,503
Sales tax receivable	358	277
Income taxes receivable	178
Inventory	2,060	1,615
Unbilled revenue	632	629
Prepaid expenses	2,037	2,481
Total current assets	16,792	37,470
Restricted cash	86	82
Deposit on equipment	332	369
Investment at fair value through profit and loss	115	142
Property and equipment	10,392	3,559
Intangible assets	30,925	32,390
Goodwill	19,171	19,635
Total assets	77,813	93,647
Current liabilities
Accounts payable and accrued liabilities	3,386	4,768
Sales tax payable	2	31
Deferred revenue	977	1,034
Income taxes payable		420
Convertible debentures – liability component		1,312
Leases	1,116	987
Deferred acquisition payments	439	740
Current liabilities	5,920	9,292
Leases	6,151	468
Deferred acquisition payments	278	497
Deferred income tax liability	7,661	8,105
Total liabilities	20,010	18,362
SHAREHOLDERS' EQUITY
Share capital	117,470	114,559
Convertible debentures – equity component		103
Contributed surplus	10,796	9,630
Accumulated other comprehensive income (loss)	2,625	(2,479)
Accumulated deficit	(73,088)	(46,528)
Equity	57,803	75,285
Total liabilities and shareholders' equity	$ 77,813	$ 93,647

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Profit or loss [abstract]
REVENUE	$ 20,665	$ 19,364
COST OF SALES	9,102	8,381
GROSS PROFIT	11,563	10,983
EXPENSES
Research and development	12,280	7,663
Sales and marketing	3,608	2,678
General and administrative	19,812	15,377
Amortization of intangible assets	4,414	2,013
Total expenses	40,114	27,731
Loss before other income (expenses) and income taxes	(28,551)	(16,748)
OTHER INCOME (EXPENSES)
Accretion	(30)	(85)
Grant and subsidy income	332	75
Interest and other income	270	279
Unrealized foreign exchange gain	227	631
Other income (expenses)	799	900
Loss before income taxes	(27,752)	(15,848)
Income taxes	1,192	(861)
NET LOSS FOR THE YEAR	(26,560)	(16,709)
Items that will be reclassified subsequently to loss
Exchange difference on translating foreign operations	5,104	(1,792)
COMPREHENSIVE LOSS FOR THE YEAR	$ (21,456)	$ (18,501)
LOSS PER SHARE - BASIC AND DILUTED	$ (1.07)	$ (0.85)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	24,897,185	19,688,487

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total	IPA Europe	BioStrand B.V.	Share Capital	Share Capital IPA Europe	Share Capital BioStrand B.V.	Convertible Debentures-Equity Component	Contributed Surplus	Accumulated Other Comprehensive (Loss) Income	Deficit
Beginning balance at Apr. 30, 2021	$ 56,924			$ 80,102			$ 127	$ 7,201	$ (687)	$ (29,819)
Beginning balance, shares at Apr. 30, 2021	19,169,216
Shares issued pursuant to deferred acquisition		$ 503	$ 29,122		$ 503	$ 29,122
Shares issued pursuant to deferred acquisition, shares		41,488	4,077,774
Shares issued pursuant to option exercise	$ 612			1,013				(401)
Shares issued pursuant to option exercise, shares	188,000
Shares issued pursuant to warrant exercise	$ 3,238			3,491				(253)
Shares issued pursuant to warrant exercise, shares	925,076
Shares issued pursuant to conversion of convertible debentures	$ 304			328			(24)
Shares issued pursuant to conversion of convertible debentures, shares	75,292
Share-based payments	$ 3,083							3,083
Comprehensive income (loss) for the period	(18,501)								(1,792)	(16,709)
Ending balance at Apr. 30, 2022	$ 75,285			114,559			103	9,630	(2,479)	(46,528)
Ending balance, shares at Apr. 30, 2022	24,476,846
Shares issued pursuant to option exercise	$ 716			1,493				(777)
Shares issued pursuant to option exercise, shares	263,537
Shares issued pursuant to conversion of convertible debentures	$ 1,315			1,418			$ (103)
Shares issued pursuant to conversion of convertible debentures, shares	309,877
Share-based payments	$ 1,943							1,943
Comprehensive income (loss) for the period	(21,456)								5,104	(26,560)
Ending balance at Apr. 30, 2023	$ 57,803			$ 117,470				$ 10,796	$ 2,625	$ (73,088)
Ending balance, shares at Apr. 30, 2023	25,050,260

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Operating activities:
Net loss for the period	$ (26,560)	$ (16,709)
Items not affecting cash:
Accretion	30	85
Amortization and depreciation	6,685	3,769
Asset impairment	2,460	167
Deferred income taxes	(926)	(336)
Foreign exchange	(146)	(519)
Gain on investment	(43)	(43)
Share-based payments	1,943	3,083
Items not affecting cash	(16,557)	(10,503)
Amounts receivable	(561)	163
Inventory	(185)	(501)
Unbilled revenue	21	91
Prepaid expenses	90	(772)
Accounts payable and accrued liabilities	(1,665)	1,462
Sales and income taxes payable and receivable	(896)	152
Deferred revenue	(80)	(13)
Net cash used in operating activities	(19,833)	(9,921)
Investing activities:
Purchase of equipment	(1,495)	(1,066)
Security depost on leases	40	(259)
Acquisition of BioStrand		(3,692)
Purchase of customer list		(191)
Deferred acquisition payment	(592)	0
Sale of QVQ Holdings BV shares	80	0
Net cash used in investing activities	(1,967)	(5,208)
Financing activities:
Proceeds on share issuance, net of transaction costs	716	3,850
Share issue cost pursuant to the acquisition of BioStrand		(5)
Repayment of leases	(1,337)	(962)
Net cash provided by financing activities	(621)	2,883
Decrease in cash during the period	(22,421)	(12,246)
Foreign exchange	740	455
Cash – beginning of the year	30,047	41,838
Cash – end of the year	8,366	30,047
Cash is comprised of:
Cash	8,280	29,965
Restricted cash	86	82
Cash paid for interest	263	38
Cash paid for income tax	$ 591	$ 1,185

Nature of Operations

Nature of Operations	12 Months Ended
Nature of Operations	Apr. 30, 2023
Disclosure Of Nature Of Operations [Abstract]
Nature Of Operations	1. NATURE OF OPERATIONS ImmunoPrecise Antibodies Ltd. (the "Company" or “IPA”) was incorporated under the laws of Alberta on November 22, 1983. The Company is listed on the NASDAQ Global Market (“Nasdaq”) under the trading ticker symbol “IPA.” The Company is a supplier of custom antibody discovery services. The address of the Company's corporate office is 3204 – 4464 Markham Street, Victoria, BC, Canada V8Z 7X8. Going concern basis The consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. The Company has incurred operating losses since its inception, including $ 26.6 million for the year ended April 30, 2023, and has accumulated a deficit of $ 73.1 million as of April 30, 2023. The Company had $ 8.4 million cash on hand as of April 30, 2023. The Company expects its cash on hand as of April 30, 2023 will be insufficient to fund the Company’s operations for at least one year from the date these financial statements are available to be issued. These conditions raise material uncertainties which cast significant doubt as to whether the Compnay will be able to continue as a going concern should it not be able to obtain financing necessary to fund its planned revenue growth and working capital requirements. The Company will need to raise additional funds to finance its operations and strategic goals and there can be no assurances that sufficient funding, including adequate financing, will be available. The ability of the Company to arrange additional financing in the future depends in part on the prevailing capital market conditions and profitability of its operations. If the Company is unable to raise sufficient funds, reductions in expenditures will be required, and this may impact the future growth plans of the Company.

Basis of Presentation

Basis of Presentation	12 Months Ended
Basis of Presentation	Apr. 30, 2023
Basis Of Accounting [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION (a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), and include the significant accounting policies as described in Note 3. These consolidated financial statements were approved by the Board of Directors. (b) Basis of measurement These consolidated financial statements have been prepared on the historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information. (c) Basis of consolidation These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA US dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA US dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA US dollar Talem Therapeutics LLC ("Talem") 100 % USA US dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with an entity and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation. (d) Functional and presentation currency The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements. The presentation currency of the Company is the Canadian dollar. Foreign currency translation Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences. Foreign currency transactions Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss. When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Apr. 30, 2023
Disclosure Of Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Business combinations Acquisitions of businesses are accounted for using the acquisition model. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognized at their fair value at the acquisition date. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain. When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. Revenue recognition The Company recognizes revenue from sale of antibodies and service agreements. Sale of antibodies: Revenue from sale of antibodies is recognized when the terms of a contract with a customer have been satisfied. This occurs when: The control over the product has been transferred to the customer; and The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Contract revenue: Revenues from contracted services are generally recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Contract revenue is recognized over time when the key milestones contained within the contract are satisfied and there is an enforceable right to payment for performance completed to date. For contracts with no enforceable right to payment when the contract is incomplete, contract revenue is recognized when the customers are satisfied with the service at the end of the contract and control of the product has been transferred to the customer. Unbilled revenue and deferred revenue: Amounts recognized as revenue in excess of billings are classified as unbilled revenue. Amounts received in advance of the performance of services are classified as deferred revenue. Cost of sales: Cost of sales includes materials, direct labor, and allocation of overhead including depreciation of lab equipment. Financial instruments Recognition and Classification The Company recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost Measurement Financial assets and liabilities at FVTPL: Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in profit or loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). Financial assets at FVTOCI: Elected investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently they are measured at fair value, with gains and losses recognized in other comprehensive income (loss). Financial assets and liabilities at amortized cost: Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Impairment of financial assets at amortized cost: The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. Irrespective of the preceding policy, the Company always measures the loss allowance of trade receivables at an amount equal to the lifetime expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets: The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in profit or loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income (loss). Financial liabilities: The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets, is recognized in profit or loss. Government assistance The Company periodically applies for financial assistance under available government incentive programs. Government assistance relating to capital expenditures is reflected as a reduction of the cost of such assets. Government assistance relating to research and development expenditures is recorded as a reduction of current year's expenses when the related expenditures are incurred. Government grant The Company periodically applies for financial assistance under available government incentive programs. The grant is recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants will be received. All funds received as part of the grant or subsidies are reflected in grant and subsidy income. Inventory Inventory consists of supplies, parts and antibodies and is valued at the lower of weighted average cost and net realizable value. Costs include acquisition, freight and other directly attributable costs. Equipment and leasehold improvements Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option The Company evaluates equipment and leasehold improvements for indications of impairment at the end of each reporting period. Impairment losses are immediately recognized in profit and loss. Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in profit or loss when the asset is derecognized. Goodwill Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Goodwill is not subject to amortization and an impairment test is performed annually or as events occur that could indicate impairment. Goodwill is reported at cost less any impairment. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”s). To test for impairment, goodwill is allocated to each of the Company’s CGUs, groups of CGUs, or an operating segment expected to benefit from the acquisition. Goodwill is tested by combining the carrying amounts of equipment and leasehold improvements, intangible assets and goodwill and comparing this to the recoverable amount. Fair value less costs of disposal is price to be received in an orderly transaction between market participants. Value in use is assessed using the present value of the expected future cash flows. Any excess of the carrying amount over the recoverable amount is recorded as impairment. Impairment charges, which are not tax affected, are recognized in profit or loss and are not reversed. During the year ended April 30, 2023, the Company recorded an impairment charge of $ 2.5 million related to the BioStrand CGU. See Note 9 for more information. Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately. Income taxes Income taxes are recognized in the statement of comprehensive income (loss), except where they relate to items recognized directly in equity, in which case the related taxes are recognized in equity. Deferred tax assets and liabilities are recognized based on the difference between the tax and accounting values of assets and liabilities and are calculated using enacted or substantively enacted tax rates for the periods in which the differences are expected to reverse. The effect of tax rate changes is recognized in profit or loss or equity, as applicable, in the period of substantive enactment. Current taxes receivable or payable are estimated on taxable income for the current year at the statutory tax rates enacted or substantively enacted. Deferred tax assets are recognized only to the extent that it is probable that future taxable profits of the relevant entity or group of entities, in a particular jurisdiction, will be available against which the assets can be utilized. As an exception, deferred tax assets and liabilities are not recognized if the temporary differences arise from the initial recognition of goodwill or an asset or liability in a transaction (other than in a business combination) that affects neither accounting profit nor taxable profit. Investment tax credits (“ITCs”) are accounted for as a reduction in the cost of the expense when there is reasonable assurance that such credits will be realized. These ITCs are used to reduce current income taxes payable. Leases At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The liabilities for leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures the right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life or the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life. Research and development Research and development cost is charged to the income statement in the period in which it is incurred. Property, plant and equipment used for research and development is capitalized and depreciated in accordance with the equipment and leasehold improvements policy. Share capital Equity instruments are contracts that give a residual interest in the net assets of the Company. The Company's common shares are classified as equity instruments. Proceeds from unit placements are allocated between common shares and warrants issued based on the residual value method, with the common shares being valued first. Share issuance costs Costs directly identifiable with the raising of share capital financing are charged against share capital. Share issuance costs incurred in advance of share subscriptions are recorded as deferred assets. Share issuance costs related to uncompleted share subscriptions are charged to operations. Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in profit or loss, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations. All equity-settled share-based payments are reflected in contributed surplus, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in contributed surplus is credited to share capital, adjusted for any consideration paid. Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense. Earnings (loss) per share Basic earnings (loss) per share is calculated by dividing the net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Dilutive earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. In periods where a net loss is incurred, potentially dilutive common shares are excluded from the loss per share calculation as the effect would be anti-dilutive and basic and diluted loss per common share is the same. In a profit year, under the treasury stock method, the weighted average number of common shares outstanding used for the calculation of diluted earnings per share assumes that the proceeds to be received on the exercise of dilutive stock options and warrants are used to repurchase common shares at the average price during the year.

Adoption of New Accounting Stan

Adoption of New Accounting Standards	12 Months Ended
Adoption of New Accounting Standards	Apr. 30, 2023
Disclosure of initial application of standards or interpretations [abstract]
Adoption of New Accounting Standards	4. ADOPTION OF NEW ACCOUNTING STANDARDS Standards adopted Onerous Contracts – Cost of Fulfilling a Contract (Amendments to IAS 37) The amendments to IAS 37 specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. Costs that relate directly to a contract can either be incremental costs of fulfilling contracts (an example would be direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts (an example would be the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract). The Company adopted this standard effective May 1, 2022. The adoption of the amendment to IAS 37 did not have an impact on the Company’s consolidated financial statements for the year ended April 30, 2023. Standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The amendments to IAS 1 provide a more general approach to the classification of liabilities based on the contractual arrangements in place at the reporting date. These amendments are effective for reporting periods beginning on or after January 1, 2024, which is our fiscal year ending April 30, 2025.

Critical Accounting Estimates A

Critical Accounting Estimates And Judgements	12 Months Ended
Critical Accounting Estimates And Judgements	Apr. 30, 2023
Critical Accounting Estimates And Judgments [Abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	5. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS The preparation of the consolidated financial statements in conformity with IFRS required estimates and judgments that affect the amounts reported in the financial statements. Actual results could differ from these estimates and judgments. Estimates are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised. Judgements Business combinations Acquisitions of a business are accounted for as a business combination if the assets acquired and liabilities assumed constitute a business in accordance with IFRS 3. Judgement is required to determine if the transaction meets the definition of a business combination. During the year ended April 30, 2022, the Company acquired all the issued and outstanding shares of Idea Family BV, BioStrand BV, BioKey BV, and BioClue BV (collectively “BioStrand”), as detailed in Note 6. Management concluded that BioStrand met the definition of a business, and accounted for the transaction as a business combination. The acquisition of BioStrand includes potential future earn-out payments dependent on the future profitability of the business. Judgement was required to determine whether the payments constitute an exchange for the business or are transactions separate from the business combination. The potential future earn-out payments to the selling shareholders of BioStrand will be accounted for separate from the business combination (see Note 18). Impairments For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”s). Management applies judgement to determine CGUs. Each asset or CGU is evaluated every reporting period to determine whether there are any indicators of impairment. If any such indicators exist, which is often judgment based, a formal estimate of recoverable amount is performed and an impairment charge is recognized to the extent that the carrying amount exceeds the recoverable amount. The Company performs a goodwill impairment test annually and when circumstances indicate that the carrying value may not be recoverable. For the purposes of impairment testing, goodwill acquired through business combinations has been allocated to three different CGUs, the Company’s Oss and Utrecht locations at IPA Europe, and BioStrand. The goodwill allocated to Oss, Utrecht, and BioStrand was $ 3.1 million, $ 4.7 million and $ 11.4 million, respectively, as at April 30, 2023. The goodwill allcoated to BioStrand includes an impairment charge during the year ended April 30, 2023 of $ 2.5 million (see Note 9). Estimates Business combinations At acquisition date, the identifiable assets acquired and liabilities assumed in a business combination are recognized at their fair value. Goodwill is measured as the excess of the consideration transferred over the net of the acquisition-date fair values of the identifiable assets acquired and liabilities assumed. Estimates are required to determine the fair value of assets acquired and liabilities assumed, and estimated fair values may vary from prices that would be achieved in an arm’s length transaction at the acquisition date (see Note 6). Impairment of long-lived assets The recoverable amount of an asset or CGU of assets is measured at the higher of fair value less costs of disposal or value in use. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period. The estimates and assumptions are subject to risk and uncertainty; hence, there is the possibility that changes in circumstances will alter these projections, which may impact the recoverable amount of the assets. In such circumstances, some or all of the carrying value of the assets may be further impaired or the impairment charge reversed with the impact recorded in profit or loss. The recoverable amount of each CGU was based on value in use, determined by discounting the future cash flows to be generated from the continuing use of the CGU. The cash flows were projected over a five-year period for the Company's Utrecht and Oss locations, and an eight-year period for BioStrand. The projections are based on past experience and actual operating results. The Company performed its annual goodwill impairment test in April 2023 and identified impairment of the BioStrand CGU. The values assigned to the key assumptions represented management’s assessment of future trends in the industry and were based on historical data from both internal and external sources. See Note 9 for details on the weighted average cost of capital used in the assesments of the three CGUs. Useful life of intangible assets Intangible assets are amortized based on estimated useful life less their estimated residual value. Significant assumptions are involved in the determination of useful life and residual values and no assurance can be given that the actual useful lives and residual values will not differ significantly from current assumptions. Actual useful life and residual values may vary depending on a number of factors including internal technical evaluation, attributes of the assets and experience with similar assets. Changes to these estimates may affect the carrying value of assets, net income (loss) and comprehensive income (loss) in future periods (see Note 8). Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit and loss over the vesting period. The Company makes assumptions to determine the estimated forfeiture rate of the share options, and these estimates are reviewed at the end of each reporting period. Changes to these estimates may affect contributed surplus and net income (loss) (see Note 12). Reclassification For the period ended October 31, 2022, the Company changed the presentation of its expense analysis from the nature of expense method to the function of expense method. In accordance with IAS 1, the Company reclassified comparative amounts beginning with the period started May 1, 2021. The reclassification is intended to provide more relevant information about the activities of separate functions at the Company, along with increased comparability to industry peers.

Acquisition of BioStrand

Acquisition of BioStrand	12 Months Ended
Acquisition of BioStrand	Apr. 30, 2023
BioStrand B.V.
Disclosure Of Business Combinations [Line Items]
ACQUISITION OF BIOSTRAND	6. ACQUISITION OF BIOSTRAND On April 13, 2022, the Company acquired all the issued and outstanding shares of BioStrand B.V., BioKey B.V., BioClue B.V. and Idea Family B.V. (collectively “BioStrand”) on terms as follows: € 2.7 million (CAD $ 3.7 million) was paid in cash on closing; 4,077,774 common shares of the Company were issued on closing; Deferred cash payment of € 0.5 million (CAD $ 0.7 million) to be paid 90 days subsequent to closing; and Deferred cash payment of € 0.5 million (CAD $ 0.6 million) to be paid over 3 years on the anniversary of the closing date. BioStrand focuses on technology in the field of bioinformatics and biotechnology related to the identification of characteristic biological sequences in proteins, RNA and DNA, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare processed biological sequences. The acquisition provides the Company with advanced omics capabilities to enhance its antibody discovery processes and offer multi-omics data analysis to its clients. The transaction was accounted for as a business combination, as the operations of BioStrand meet the definition of a business. As the transaction was accounted for as a business combination, legal and consulting costs of $ 0.7 million and $ 0.1 million, respectively, were expensed during the year ended April 30, 2022. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets will represent the sales growth potential and assembled workforce of BioStrand. During the three months ended July 31, 2022, the Company recorded the right-of-use assets and lease liabilities in connection with building and vehicle leases at BioStrand. During the three months ended October 31, 2022, the Company adjusted goodwill upon the finalization of the deferred cash payment paid 90 days subsequent to closing. Both adjustments occurred during the measurement period and were applied retrospectively. The Company has allocated the purchase price as follows: (in thousands) $ Cash 4,985 Common shares of the Company 29,126 Fair value of consideration 34,111 Cash 36 Amounts receivable 80 Unbilled revenue 8 Equipment and right-of-use assets 247 Intellectual property (not deductible for tax purposes) 28,459 Proprietary processes (not deductible for tax purposes) 391 Goodwill (not deductible for tax purposes) 12,658 Accounts payable and accrued liabilities assumed ( 342 ) Deferred revenue 9 Leases ( 223 ) Deferred income tax liability ( 7,212 ) 34,111 The intellectual property assets are primarily comprised of acquired technology assets that are expected to have a useful life of 15 years . The fair value of the 4,077,774 common shares issued ($ 29.1 million) was determined based on the Canadian dollar equivalent of the consideration required of € 21.3 million pursuant to the share purchase agreement using the closing stock price at` the date of the acquisition. The common shares are subject to an escrow agreement, and will be released to the vendors on the following schedule: 15 % one year after closing, 20 % two years after closing, and 65 % three years after closing. The operating results for BioStrand have been recognized in the consolidated statement of comprehensive loss beginning on April 13, 2022, the effective date of control. During the year ended April 30, 2022, the Company recorded a net loss of $ 0.2 million related to BioStrand. The deferred cash payments of € 1.0 million was fair valued on the date of acquisition using a discounted cash flow model. The changes in the value of the subsequent payments during the years ended April 30, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2021 — Amount at date of acquisition 1,317 Foreign exchange ( 12 ) Balance, April 30, 2022 1,305 Foreign exchange 45 Accretion 27 Working capital adjustment ( 68 ) Deferred acquisition payment ( 592 ) Balance, April 30, 2023 717 Less: Current portion ( 439 ) Non-current portion 278 The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments (see Note 18).

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Apr. 30, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Total Cost: Balance, April 30, 2021 96 36 49 2,730 94 353 5,048 — 8,406 Additions 39 3 — 311 1 — 991 138 1,483 Acquisition of BioStrand 24 — — 69 152 — — — 245 Disposals ( 21 ) ( 5 ) — — — — — — ( 26 ) Lease modification — — — ( 22 ) — — — — ( 22 ) Subsidy reimbursement — — — — — — ( 106 ) — ( 106 ) Asset impairment — — — ( 363 ) — — — — ( 363 ) Foreign exchange ( 2 ) 1 ( 2 ) ( 139 ) ( 8 ) — ( 261 ) — ( 411 ) Balance, April 30, 2022 136 35 47 2,586 239 353 5,672 138 9,206 Additions 138 — — 7,593 — 101 1,064 28 8,924 Completion of work-in-process — — — — — 166 — ( 166 ) — Disposals ( 3 ) — — ( 1,290 ) ( 95 ) — ( 700 ) — ( 2,088 ) Foreign exchange 17 18 3 196 23 6 437 — 700 Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 — 16,742 Accumulated Depreciation: Balance, April 30, 2021 61 28 42 1,334 27 296 2,594 — 4,382 Depreciation 31 6 7 698 23 51 940 — 1,756 Disposals ( 21 ) ( 5 ) — — — — — — ( 26 ) Asset impairment — — — ( 196 ) — — — — ( 196 ) Foreign exchange ( 1 ) — ( 2 ) ( 100 ) ( 4 ) 1 ( 163 ) — ( 269 ) Balance, April 30, 2022 70 29 47 1,736 46 348 3,371 — 5,647 Depreciation 84 3 — 1,109 58 40 977 — 2,271 Disposals ( 3 ) — — ( 1,274 ) ( 57 ) — ( 507 ) — ( 1,841 ) Foreign exchange 6 1 3 181 10 — 72 — 273 Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Net Book Value: April 30, 2022 66 6 — 850 193 5 2,301 138 3,559 April 30, 2023 131 20 — 7,333 110 238 2,560 — 10,392

Intangible Assets

Intangible Assets	12 Months Ended
Intangible Assets	Apr. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS	8. INTANGIBLE ASSETS Changes in the value of the intangible assets during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Internally Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2021 33 4,089 7,635 138 — 11,895 Costs expensed — — — — 191 191 Acquisition of BioStrand — 28,459 391 — — 28,850 Foreign exchange — ( 634 ) ( 667 ) ( 12 ) ( 11 ) ( 1,324 ) Balance, April 30, 2022 33 31,914 7,359 126 180 39,612 Foreign exchange — 3,229 744 13 18 4,004 Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Accumulated Amortization: Balance, April 30, 2021 1 1,445 4,391 — — 5,837 Amortization 7 398 1,577 — 31 2,013 Foreign exchange — ( 150 ) ( 477 ) — ( 1 ) ( 628 ) Balance, April 30, 2022 8 1,693 5,491 — 30 7,222 Amortization 7 2,710 1,477 128 92 4,414 Foreign exchange ( 1 ) 372 665 9 10 1,055 Balance, April 30, 2023 14 4,775 7,633 137 132 12,691 Net Book Value: April 30, 2022 25 30,221 1,868 126 150 32,390 April 30, 2023 19 30,368 470 2 66 30,925

Goodwill

Goodwill	12 Months Ended
Goodwill	Apr. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Goodwill	9. GOODWILL The goodwill was acquired as a result of the acquisitions of U-Protein, IPA Europe and, BioStrand. The changes in the value of goodwill during the year ended April 30, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2021 7,777 Foreign exchange ( 677 ) Acquisition of BioStrand 12,535 Balance, April 30, 2022 19,635 Foreign exchange 1,996 Asset impairment ( 2,460 ) Balance, April 30, 2023 19,171 Impairment testing For annual impairment testing, goodwill is allocated to the following cash-generating units: (in thousands) April 30, April 30, Oss 3,109 2,823 Utrecht 4,710 4,277 BioStrand 11,352 12,535 19,171 19,635 The recoverable amount of each cash-generating unit was based on value-in-use calculations, and determined using a five-year forecast for Utrecht and Oss and an eight-year forecast for BioStrand, followed by a terminal growth rate determined by management. The present value of the forecasted cash flows of each cash-generating unit is determined by applying a discount rate reflecting a current market assessment of the time value of money and risks specific to the cash-generating units. The recoverable amount, growth rate assumptions and discount rates for each cash-generating unit as at April 30, 2023 and 2023 are as follows: Recoverable amount Terminal growth rates Discount rates (in thousands) 2023 2022 2023 2022 2023 2022 Oss 6,723 9,493 2.2 % 2.0 % 28.1 % 14.3 % Utrecht 11,405 12,483 2.2 % 2.0 % 24.1 % 14.3 % BioStrand 31,546 — 2.5 % — 33.1 % — The terminal growth rates reflect the average GDP growth rate of the Netherlands and Belgium. The discount rates reflect management’s assessment of market and specific risk of the cash-generating units. Both the Oss and Utrecht cash-generating units operate in the same region and are included in the same operating segment of the Company. The cash flow forecasts include a key management assumption that future profit margins will remain stable, and is based on previous performance of the cash-generating units. The assumption for future profit margins is based on management’s review of the prior three years of performance of the cash-generating units. During the year ended April 30, 2023, the Compay recorded an impairment loss of $ 2.5 million for the BioStrand CGU. The loss was recorded as a reduction in goodwill. The primary factor for the impairment included a rise in the discount rate as compared to the prior year, along with a delay in expected cash flows in the forecast. The increased discount rate relates to increases in the forecast risk for the BioStrand CGU, increased economic risk, and increased global interest rates as compared to the prior year.

Convertible Debentures

Convertible Debentures	12 Months Ended
Convertible Debentures	Apr. 30, 2023
Convertible Debentures [Abstract]
CONVERTIBLE DEBENTURES	10. CONVERTIBLE DEBENTURES On May 15, 2020, the Company closed a non-brokered private placement financing by issuing 10 % convertible debentures (“New Debentures”) for total proceeds of $ 2.59 million. On May 27, 2020, the Company issued an additional $ 0.04 million of the 10 % New Debentures. In total, the Company issued $ 2.6 million of the New Debentures. The New Debentures are unsecured, bear interest at a rate of 10 % per year and payable at maturity. The maturity date is May 15, 2022 for $ 2.59 million of the New Debentures and May 22, 2022 for $ 0.04 million of the New Debentures. The principal amount of the New Debentures may be convertible, at the option of the holder, into units of the Company at a conversion price of $ 4.25 per share. The Company may force convert the principal amount of the New Debentures at $4.25 per share if the average closing price is equal to or greater than $7.50 for 20 trading days. The fair value of the New Debentures at the time of issue was calculated as the discounted cash flows assuming a 15 % effective interest rate. The fair value of the equity component was determined at the time of issue as the difference between the face value and the fair value of the New Debentures. On initial recognition, the Company bifurcated $ 2.4 million to the carrying value of the New Debentures and $ 0.2 million to the equity component. Under the financing, the Company paid finder’s cash commissions totaling $ 0.08 million and incurred legal and filing fees of $ 0.03 million. The transaction costs were allocated pro-rata based on the carrying values of the New Debentures and the equity component, with $ 0.1 million allocated to the New Debentures and $ 0.01 million allocated to the equity component. The changes in the value of the New Debentures during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Liability Equity Balance, April 30, 2021 1,531 127 Accretion expense 85 — Conversion to shares ( 304 ) ( 24 ) Balance, April 30, 2022 1,312 103 Accretion expense 3 — Conversion to shares ( 1,315 ) ( 103 ) Balance, April 30, 2023 — —

Leases

Leases	12 Months Ended
Leases	Apr. 30, 2023
Presentation of leases for lessee [abstract]
LEASES	11. LEASES The Company has leases for lab and office space, automobiles and one item of lab equipment. Each lease is reflected in the consolidated statement of financial position as a right-of-use asset and a lease liability. The Company classifies right-of-use assets in a consistent manner to its property and equipment. The following is a schedule of the Company’s future minimum lease payments related to the equipment and automobiles under finance lease and the office lease obligation: (in thousands) $ 2024 1,548 2025 1,033 2026 993 2027 989 2028 983 More than 5 years 3,849 Total minimum lease payments 9,395 Less: imputed interest ( 2,128 ) Total present value of minimum lease payments 7,267 Less: Current portion ( 1,116 ) Non-current portion 6,151 Total cash outflow for leases during the year ended April 30, 2023 was $ 1.3 million (2022 - $ 1.0 million). The nature of the Company’s leases by type of right-of-use asset as at April 30, 2023 is as follows: Right-of-use asset type No. of right-of-use assets leased Range of remaining term Average remaining lease term No. of leases with extension options No. of leases with options to purchase No. of leases with variable payments linked to an index No. of leases with termination options Lab and office facilities 4 0.5 - 9 years 3 years 4 — 3 2 Automobiles 6 1.5 - 4 years 2 years — — 6 6 Right-of-use assets The Company reviews long-lived assets with finite useful lives for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable. During the year ended April 30, 2022, a significant change in the planned use of a right-of-use asset related to leased office space indicated possible impairment of the asset. Due to the nature of the leased space, the Company determined the recoverable amount to be nominal, and recorded an impairment charge of $ 0.2 million in general & administrative expense, the full carrying value of the asset. During the year ended April 30, 2023, the Company recorded a right-of-use asset of $ 6.2 million upon commencement of a new lease at the Utrecht, the Netherlands location. The lease includes an initial term of five years , and a renewal option for an additional five years . The Company has determined that it is reasonably certain to exercise the renewal option. The changes in the value of right-of-use assets during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Building Automobile Lab Total Cost: Balance, April 30, 2021 2,730 94 623 3,447 Additions 311 1 — 312 Acquisition of BioStrand 69 152 — 221 Lease modification ( 22 ) — — ( 22 ) Loss on impairment ( 369 ) — — ( 369 ) Foreign exchange ( 133 ) ( 8 ) 28 ( 113 ) Balance, April 30, 2022 2,586 239 651 3,476 Additions 7,593 — — 7,593 Disposals ( 1,290 ) ( 95 ) ( 687 ) ( 2,072 ) Foreign exchange 196 23 36 255 Balance, April 30, 2023 9,085 167 — 9,252 Accumulated Depreciation: Balance, April 30, 2021 1,334 27 220 1,581 Depreciation 698 23 224 945 Loss on impairment ( 196 ) — — ( 196 ) Foreign exchange ( 100 ) ( 4 ) 16 ( 88 ) Balance, April 30, 2022 1,736 46 460 2,242 Depreciation 1,109 58 198 1,365 Disposals ( 1,274 ) ( 57 ) ( 507 ) ( 1,838 ) Foreign exchange 181 10 ( 151 ) 40 Balance, April 30, 2023 1,752 57 — 1,809 Net Book Value: April 30, 2022 850 193 191 1,234 April 30, 2023 7,333 110 — 7,443 Lease payments not recognized as a liability The Company has elected not to recognize a lease liability for leases with an expected term of 12 months or less. Additionally, certain variable lease payments are not permitted to be recognized as lease liabilities and are recognized in profit and loss as incurred. The expense relating to payments not included in the measurement of the lease liability during the years ended April 30, 2023 and 2022 are as follows: (in thousands) 2023 2022 Leases of low value assets 40 32 Variable lease payments 215 136 255 168

Share Capital

Share Capital	12 Months Ended
Share Capital	Apr. 30, 2023
Disclosure of classes of share capital [abstract]
SHARE CAPITAL	12. SHARE CAPITAL a) Authorized: Unlimited common shares without par value. b) Share capital transactions: 2022 Transactions On May 3, 2021, the Company issued 41,488 common shares pursuant to the final deferred payment for the acquisition of IPA Europe. The common shares were valued at $ 0.5 million. On April 13, 2022, the Company issued 4,077,774 common shares pursuant to the acquisition of BioStrand (Note 6). The common shares were valued at $ 29.1 million. During the year ended April 30, 2022, the Company issued 188,000 common shares pursuant to the exercise of stock options for total gross proceeds of $ 0.6 million. A value of $ 0.4 million was transferred from contributed surplus to share capital as a result. The weighted average share price at the dates the stock options were exercised was $ 7.95 . During the year ended April 30, 2022, the Company issued 925,076 common shares pursuant to the exercise of warrants and finder’s warrants for total gross proceeds of $ 3.2 million. A value of $ 0.3 million was transferred from contributed surplus to share capital as a result. During the year ended April 30, 2022, the Company issued 75,292 common shares with a value of $ 0.3 million pursuant to the conversion of $ 0.3 million principal balance of convertible debentures. 2023 Transactions During the year ended April 30, 2023, the Company issued 263,537 common shares pursuant to the exercise of stock options for total gross proceeds of $ 0.7 million. A value of $ 0.8 million was transferred from contributed surplus to share capital as a result. The weighted average share price at the dates the stock options were exercised was US $ 4.50 . During the year ended April 30, 2023, the Company issued 309,877 common shares with a value of $ 1.3 million pursuant to the conversion of $ 1.3 million principal balance of convertible debentures. c) Options The following table summarizes stock option awards during the years ended April 30, 2023 and 2022, including the fair value determined using the Black-Scholes option pricing model: Grant date Stock options granted Exercisable price/option Awarded to Share price on grant date Dividend yield Expected volatility Risk-free rate Expected life Fair value May 9, 2021 (3) 10,000 7.72 (7) Strategic Board Members 9.42 0 % 78 % 0.70 % 5.0 years $ 0.06 million June 13, 2021 (4) 43,750 7.14 (7) Consultant 8.63 0 % 78 % 0.71 % 3.0 years $ 0.2 million August 7, 2021 (2) 45,000 9.19 Employees 9.19 0 % 79 % 0.80 % 5.0 years $ 0.3 million January 2, 2022 (1) 28,250 6.89 Directors 6.89 0 % 77 % 1.18 % 4.0 years $ 0.1 million January 7, 2022 (2) 225,000 7.94 Officers and employees 7.94 0 % 77 % 1.42 % 5.0 years $ 1.1 million January 7, 2022 (2) 113,000 7.94 Employees 7.94 0 % 77 % 1.42 % 4.7 years $ 0.5 million January 13, 2022 (5) 15,000 8.30 Officer 8.30 0 % 77 % 1.43 % 1.0 years $ 0.04 million January 13, 2022 (2) 24,000 8.30 Employees 8.30 0 % 77 % 1.43 % 4.7 years $ 0.1 million March 11, 2022 (6) 25,000 6.35 Consultant 4.67 0 % 76 % 1.77 % 2.0 years $ 0.03 million May 15, 2022 (2) 80,000 5.79 Employees 3.79 0 % 77 % 2.73 % 5.0 years $ 0.3 million February 19, 2023 (1) 29,060 4.10 (7) Directors 4.10 (7) 0 % 77 % 3.57 % 4.0 years $ 0.1 million February 19, 2023 (2) 609,452 4.10 (7) Officers and employees 4.10 (7) 0 % 77 % 3.57 % 5.0 years $ 2.2 million (1) Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. (2) Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date . (3) Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date. (4) The option vested immediately. (5) Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. (6) Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date. (7) Priced in US dollars Expected volatility of options granted is based on the historical volatility of the company from January 1, 2019 to the option grant date. During the year ended April 30, 2023, the Company has recorded $ 1.9 million (2022 - $ 3.1 million) of share-based payments expense. The changes in the stock options for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 (outstanding) 1,358,900 7.93 3.11 Granted 529,000 7.98 — Exercised ( 188,000 ) 3.26 — Expired ( 60,250 ) 10.75 — Forfeited ( 15,500 ) 20.30 — Balance, April 30, 2022 (outstanding) 1,624,150 8.29 2.88 Granted 718,512 5.58 — Exercised ( 318,725 ) 3.27 — Expired ( 115,174 ) 9.35 — Forfeited ( 24,335 ) 9.45 — Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Unvested ( 813,845 ) 5.95 4.55 Exercisable, April 30, 2023 1,070,583 9.61 2.30 Details of the options outstanding as at April 30, 2023 are as follows: Expiry Date Exercise Remaining Options Unvested Exercisable September 24, 2023 4.75 0.40 19,000 - 19,000 November 7, 2023 4.10 0.52 20,000 - 20,000 December 31, 2023 5.00 0.67 180,000 - 180,000 January 11, 2024 5.00 0.70 60,000 - 60,000 September 1, 2025 8.50 2.34 250,000 - 250,000 January 6, 2026 20.30 2.69 210,000 - 210,000 May 9, 2026 (1) 10.46 3.03 10,000 6,667 3,333 January 2, 2026 6.89 2.68 28,250 - 28,250 January 7, 2027 7.94 3.69 332,666 110,000 222,666 January 7, 2027 8.30 3.71 31,000 5,333 25,667 February 22, 2024 6.35 0.82 25,000 - 25,000 May 15, 2027 5.79 4.04 80,000 53,333 26,667 February 19, 2027 (2) 5.55 3.81 29,060 29,060 - February 19, 2028 (2) 5.55 4.81 609,452 609,452 - 8.03 3.27 1,884,428 813,845 1,070,583 (1) Exercise price of US $ 7.72 . The figure in the table above is translated at the April 30, 2023 rate. (2) Exercise price of US $ 4.10 . The figure in the table above is translated at the April 30, 2023 rate. d) Warrants The changes in the warrants for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 878,300 3.50 0.90 Exercised ( 878,300 ) 3.50 — Balance, April 30, 2023 and 2022 — — — d) Finder’s Warrants The changes in the finder’s warrants for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2021 176,888 16.12 3.75 Exercised ( 46,777 ) 3.50 — Balance, April 30, 2022 130,111 21.59 3.77 Exercised — — — Balance, April 30, 2023 130,111 22.77 2.77 Details of the finder’s warrants outstanding as at April 30, 2023 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 22.77 2.77 130,111 (1) Exercise price of US $ 16.81 . The figure in the table above is translated at the April 30, 2023 rate.

Employee Remuneration

Employee Remuneration	12 Months Ended
Employee Remuneration	Apr. 30, 2023
Disclosure of employee benefits expenses [abstract]
EMPLOYEE REMUNERATION	13. EMPLOYEE REMUNERATION Expenses recognized for employee benefits for the years ended April 30, 2023 and 2022 are detailed below: (in thousands) 2023 2022 Wages, salaries 10,433 8,600 Employee benefits 926 798 Payroll taxes 939 714 Severance 194 8 Share-based payments 1,943 3,083 14,435 13,203

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Apr. 30, 2023
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	14. RELATED PARTY TRANSACTIONS Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management consists of Dr. Jennifer Bath, President and CEO; Brad McConn, CFO; Dr. Stefan Lang, former Chief Business Officer; Dr. Ilse Roodink, Chief Scientific Officer; Lisa Helbling, former Chief Financial Officer, Dr. Yasmina Abdiche, former Chief Scientific Officer; and Directors of the Company. During the years ended April 30, 2023 and 2022, the compensation for key management is as follows: (in thousands) 2023 2022 Salaries and other short-term benefits 2,632 2,531 Severance (included in salaries) 183 8 Share-based payments 986 1,388 Director compensation (included in salaries) 335 355 4,136 4,282 At April 30, 2023 , included in accounts payable and accrued liabilities is $ 0.9 million (April 30, 2022 - $ 0.4 million) due to related parties. The amounts payable are non-interest bearing and unsecured. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties, unless otherwise noted.

Capital Management

Capital Management	12 Months Ended
Capital Management	Apr. 30, 2023
Capital Management [Abstract]
CAPITAL MANAGEMENT	15. CAPITAL MANAGEMENT The Company’s objectives when managing capital are to ensure sufficient liquidity for operations and adequate funding for growth and capital expenditures while maintaining an efficient balance between debt and equity. The capital structure of the Company consists of shareholders’ equity of $ 60.6 million. The Company makes adjustments to its capital structure upon approval from its Board of Directors, in light of economic conditions and the Company’s working capital requirements. There were no changes in the Company’s approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

Financial Instruments

Financial Instruments	12 Months Ended
Financial Instruments	Apr. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	16. FINANCIAL INSTRUMENTS The Company’s financial instruments include cash, amounts receivable, restricted cash, investment, accounts payable and accrued liabilities, debentures, loans payable, leases and deferred acquisition payments. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value, by reference to the reliability of the inputs used to estimate the fair values. Level 1 – applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 – applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 – applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The fair value of investment is determined based on “Level 2” inputs as its value under the equity method was the best approximation of its fair value. As at April 30, 2023, the Company believes the carrying values of cash, amounts receivable, restricted cash, accounts payable and accrued liabilities, leases and deferred acquisition payments approximate their fair values because of their nature and relatively short maturity dates or durations. Concentration of risk: Concentrations of credit risk Credit risk relates to cash, restricted cash and amounts receivable and arises from the possibility that counterparty to an instrument may fail to perform. At April 30, 2023, all of the Company’s cash was held with tier one banks. Details of amounts receivable and allowances for doubtful accounts as at April 30, 2023 and 2022 are as follows: (in thousands) 2023 2022 Amounts receivable 3,280 2,539 Allowance for doubtful accounts ( 33 ) ( 36 ) Amounts receivable, net 3,247 2,503 Currency risk The Company operates in the US and Europe which gives rise to exposure to market risks from changes in foreign currency values. Most significantly, the Company is exposed to potential currency fluctuations between US and Canadian dollars, which was translated at 1.3548 at April 30, 2023, and the Euro and Canadian dollar, which was translated at 1.4933 at April 30, 2023. Fluctuations in the exchange rate could impact profitability. At April 30, 2023, the Company is exposed to currency risk through the following assets and liabilities denominated in US dollars and Euros: Euros US Dollars (in thousands) (€) (US $) Cash 2,465 2,193 Amounts receivable 1,236 679 Investment 82 — 3,783 2,872 Accounts payable and accrued liabilities ( 867 ) ( 1,700 ) Deferred acquisition payments ( 336 ) — Leases ( 664 ) ( 70 ) ( 1,867 ) ( 1,770 ) Net 1,916 1,102 Liquidity risk: The Company’s approach to managing its obligations is to maintain sufficient resources to meet its obligations when due without undue risk to the Company. The Company monitors its cash requirements on an ongoing basis to ensure that there are sufficient resources for operations as well as to fund anticipated leasing, capital and development expenditures. In addition, the Company manages its cash to meet its obligations and to fund general and administrative costs. Contractual cash flow requirements as at April 30, 2023 were as follows: < 1 1 - 2 2 - 5 >5 Total (in thousands) $ $ $ $ $ Accounts payable and accrued liabilities 3,386 — — — 3,386 Leases 1,548 1,033 2,965 3,849 9,395 Total 4,934 1,033 2,965 3,849 12,781

Inventories

Inventories	12 Months Ended
Inventories	Apr. 30, 2023
Inventories [Abstract]
INVENTORIES	17. INVENTORIES Inventories as at April 30, 2023 and 2022 consist of the following: (in thousands) 2023 2022 Supplies and parts 1,344 1,418 Antibodies 206 197 Work in process 510 — 2,060 1,615

Commitments

Commitments	12 Months Ended
Commitments	Apr. 30, 2023
Commitments [Abstract]
COMMITMENTS	18. COMMITMENTS The Company entered into a lease agreement for a new facility for its Oss, the Netherlands location on October 16, 2021. The lease will have a five-year term with an optional five-year extension, and is estimated to commence January 1, 2024 at an estimated annual cost of € 0.5 million indexed for inflation. The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments based on 20 % of the EBITDA of BioStrand, as defined in the share purchase agreement, over a 7-year period, which shall not exceed in total € 12.0 million. The Company has determined these payments relate to post-acquisition services because they are contingent on the employment of two key employees and will be expensed in the period earned. As of April 30, 2023, the Company's unpaid commitment related to the BioStrand earnout is € 12.0 million.

Grant and Subsidy Income

Grant and Subsidy Income	12 Months Ended
Grant and Subsidy Income	Apr. 30, 2023
Grant And Subsidy Income [Abstract]
GRANT AND SUBSIDY INCOME	19. GRANT AND SUBSIDY INCOME During May 2022, the Company received a € 0.5 million round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. The Company received the first disbursement of € 0.2 million during the three months ended July 31, 2022.

Segmented Information and Econo

Segmented Information and Economic Dependence	12 Months Ended
Segmented Information and Economic Dependence	Apr. 30, 2023
Disclosure of operating segments [abstract]
SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE	20. SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE At April 30, 2023 and April 30, 2022, the Company has one reportable segment, being antibody production and related services. The Company’s revenues are allocated to geographic regions for the year ended April 30, 2023 and 2022 as follows: Years ended (in thousands) 2023 2022 United States of America 9,365 6,816 Europe 9,450 9,429 Canada 618 572 Australia 630 1,540 Other 602 1,007 20,665 19,364 The Company’s revenues are allocated according to revenue types for the year ended April 30, 2023 and 2022 as follows: Years ended (in thousands) 2023 2022 Project revenue 18,677 17,356 Product sales revenue 1,747 1,652 Cryostorage revenue 241 356 20,665 19,364 As at April 30, 2023, all deferred revenue is expected to be recognized over the next twelve months. The Company’s non-current assets are allocated to geographic regions as of April 30, 2023 and 2022 as follows: April 30, April 30, North America - Corporate 89 76 North America 1,025 1,481 Belgium 40,406 41,355 Netherlands 19,501 13,265 61,021 56,177 Geographic segmentation of the Company’s net income (loss) for the year ended April 30, 2023 and 2022 is as follows: Years ended (in thousands) 2023 2022 North America - Corporate ( 8,422 ) ( 9,340 ) North America ( 12,601 ) ( 11,424 ) Belgium ( 7,024 ) ( 215 ) Netherlands 1,487 4,270 ( 26,560 ) ( 16,709 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the year ended April 30, 2023 and 2022 is as follows: Years ended Interest and accretion (in thousands) 2023 2022 North America - Corporate 39 258 North America 19 51 Belgium 20 3 Netherlands 318 107 396 419 Years ended Amortization and depreciation (in thousands) 2023 2022 North America - Corporate 14 56 North America 720 778 Belgium 2,543 — Netherlands 3,408 2,935 6,685 3,769

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
Supplemental Cash Flow Information	Apr. 30, 2023
Statement of cash flows [abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	21. SUPPLEMENTAL CASH FLOW INFORMATION Non-cash investing and financing transactions (in thousands) April 30, April 30, Acquisition of building and equipment by lease 7,593 312 Settlement of convertible debentures 1,315 304 Fair value of shares issued pursuant to deferred acquisition payment to IPA Europe — 503 The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 1,237 ( 592 ) — — 27 ( 23 ) 649 Convertible debentures 1,312 — — ( 1,315 ) 3 — — Leases 1,455 ( 1,337 ) 7,593 — — ( 444 ) 7,267 Total 4,004 ( 1,929 ) 7,593 ( 1,315 ) 30 ( 467 ) 7,916 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign April 30, Deferred acquisition payments 498 — 1,248 ( 503 ) — ( 6 ) 1,237 Convertible debentures 1,531 — — ( 304 ) 85 — 1,312 Leases 1,926 ( 962 ) 533 — — ( 42 ) 1,455 Total 3,955 ( 962 ) 1,781 ( 807 ) 85 ( 48 ) 4,004

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Apr. 30, 2023
Disclosure Of Income Taxes [Abstract]
INCOME TAXES	22. INCOME TAX Income tax expense differs from the amount that would be computed by applying the federal and provincial statutory tax rates of 27 % (2021 – 27 %) to the earnings before income taxes. The reasons for the differences and related tax effects are as follows: 2023 2022 $ $ Earnings (loss) before income taxes ( 27,752 ) ( 15,848 ) Income taxes (recovery) on earnings before income taxes, at above basic rate ( 7,493 ) ( 3,627 ) Increase (decrease) in taxes resulting from: Nondeductible expenses 8 322 Estimated SR&ED ITC ( 198 ) — Effects of tax rate change and foreign exchange 209 12 Deferred income tax asset recognized — ( 138 ) Tax rate difference by jurisdiction 948 ( 359 ) Tax benefits not recognized 4,885 4,651 Impairment loss 602 — Prior year tax assessments and adjustments ( 420 ) — Other 267 — Income taxes (recovery) ( 1,192 ) 861 2023 2022 $ $ Current income taxes ( 242 ) 1,390 Deferred income taxes (recovery) ( 950 ) ( 529 ) Income taxes (recovery) ( 1,192 ) 861 Temporary differences give rise to the following deferred income tax assets and liabilities: 2023 2022 $ $ Other tax pools 31 ( 20 ) Capital assets net of lease liabilities ( 61 ) 8 Inventory and intangible assets ( 7,631 ) ( 8,093 ) Recognized deferred income tax liabilities ( 7,661 ) ( 8,105 ) 2023 2022 $ $ Non-capital losses carried forward (expire from 2026 to 2039 ) 9,930 10,514 Other tax pools — 1,373 Capital losses carried forward 295 194 Capital assets net of lease liabilities 20 13 Financing costs 746 979 Less: unrecognized deferred income tax asset ( 10,991 ) ( 13,073 ) Unrecognized deferred income tax liabilities — —

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Apr. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS	23. SUBSEQUENT EVENTS Subsequent to April 30, 2023, the Company entered into a lease agreement for its Victoria location. The lease is estimated to commence during the three months ended July 31, 2023, at an estimated annual cost of $ 0.4 million when payments begin on January 1, 2024.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Apr. 30, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Business combinations	Business combinations Acquisitions of businesses are accounted for using the acquisition model. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognized at their fair value at the acquisition date. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain. When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.
Revenue recognition	Revenue recognition The Company recognizes revenue from sale of antibodies and service agreements. Sale of antibodies: Revenue from sale of antibodies is recognized when the terms of a contract with a customer have been satisfied. This occurs when: The control over the product has been transferred to the customer; and The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Contract revenue: Revenues from contracted services are generally recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Contract revenue is recognized over time when the key milestones contained within the contract are satisfied and there is an enforceable right to payment for performance completed to date. For contracts with no enforceable right to payment when the contract is incomplete, contract revenue is recognized when the customers are satisfied with the service at the end of the contract and control of the product has been transferred to the customer. Unbilled revenue and deferred revenue: Amounts recognized as revenue in excess of billings are classified as unbilled revenue. Amounts received in advance of the performance of services are classified as deferred revenue. Cost of sales: Cost of sales includes materials, direct labor, and allocation of overhead including depreciation of lab equipment.
Financial instruments	Financial instruments Recognition and Classification The Company recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost Measurement Financial assets and liabilities at FVTPL: Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in profit or loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). Financial assets at FVTOCI: Elected investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently they are measured at fair value, with gains and losses recognized in other comprehensive income (loss). Financial assets and liabilities at amortized cost: Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Impairment of financial assets at amortized cost: The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. Irrespective of the preceding policy, the Company always measures the loss allowance of trade receivables at an amount equal to the lifetime expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets: The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in profit or loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income (loss). Financial liabilities: The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets, is recognized in profit or loss.
Government assistance	Government assistance The Company periodically applies for financial assistance under available government incentive programs. Government assistance relating to capital expenditures is reflected as a reduction of the cost of such assets. Government assistance relating to research and development expenditures is recorded as a reduction of current year's expenses when the related expenditures are incurred.
Government grant	Government grant The Company periodically applies for financial assistance under available government incentive programs. The grant is recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants will be received. All funds received as part of the grant or subsidies are reflected in grant and subsidy income.
Inventory	Inventory Inventory consists of supplies, parts and antibodies and is valued at the lower of weighted average cost and net realizable value. Costs include acquisition, freight and other directly attributable costs.
Equipment and leasehold improvements	Equipment and leasehold improvements Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option The Company evaluates equipment and leasehold improvements for indications of impairment at the end of each reporting period. Impairment losses are immediately recognized in profit and loss.
Intangible assets	Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in profit or loss when the asset is derecognized.
Goodwill	Goodwill Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Goodwill is not subject to amortization and an impairment test is performed annually or as events occur that could indicate impairment. Goodwill is reported at cost less any impairment. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”s). To test for impairment, goodwill is allocated to each of the Company’s CGUs, groups of CGUs, or an operating segment expected to benefit from the acquisition. Goodwill is tested by combining the carrying amounts of equipment and leasehold improvements, intangible assets and goodwill and comparing this to the recoverable amount. Fair value less costs of disposal is price to be received in an orderly transaction between market participants. Value in use is assessed using the present value of the expected future cash flows. Any excess of the carrying amount over the recoverable amount is recorded as impairment. Impairment charges, which are not tax affected, are recognized in profit or loss and are not reversed. During the year ended April 30, 2023, the Company recorded an impairment charge of $ 2.5 million related to the BioStrand CGU. See Note 9 for more information.
Impairment of long-lived assets	Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately.
Income taxes	Income taxes Income taxes are recognized in the statement of comprehensive income (loss), except where they relate to items recognized directly in equity, in which case the related taxes are recognized in equity. Deferred tax assets and liabilities are recognized based on the difference between the tax and accounting values of assets and liabilities and are calculated using enacted or substantively enacted tax rates for the periods in which the differences are expected to reverse. The effect of tax rate changes is recognized in profit or loss or equity, as applicable, in the period of substantive enactment. Current taxes receivable or payable are estimated on taxable income for the current year at the statutory tax rates enacted or substantively enacted. Deferred tax assets are recognized only to the extent that it is probable that future taxable profits of the relevant entity or group of entities, in a particular jurisdiction, will be available against which the assets can be utilized. As an exception, deferred tax assets and liabilities are not recognized if the temporary differences arise from the initial recognition of goodwill or an asset or liability in a transaction (other than in a business combination) that affects neither accounting profit nor taxable profit. Investment tax credits (“ITCs”) are accounted for as a reduction in the cost of the expense when there is reasonable assurance that such credits will be realized. These ITCs are used to reduce current income taxes payable.
Leases	Leases At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The liabilities for leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures the right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life or the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life.
Research and development	Research and development Research and development cost is charged to the income statement in the period in which it is incurred. Property, plant and equipment used for research and development is capitalized and depreciated in accordance with the equipment and leasehold improvements policy.
Share capital	Share capital Equity instruments are contracts that give a residual interest in the net assets of the Company. The Company's common shares are classified as equity instruments. Proceeds from unit placements are allocated between common shares and warrants issued based on the residual value method, with the common shares being valued first.
Share issuance costs	Share issuance costs Costs directly identifiable with the raising of share capital financing are charged against share capital. Share issuance costs incurred in advance of share subscriptions are recorded as deferred assets. Share issuance costs related to uncompleted share subscriptions are charged to operations.
Share-based payments	Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in profit or loss, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations. All equity-settled share-based payments are reflected in contributed surplus, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in contributed surplus is credited to share capital, adjusted for any consideration paid. Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share is calculated by dividing the net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Dilutive earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. In periods where a net loss is incurred, potentially dilutive common shares are excluded from the loss per share calculation as the effect would be anti-dilutive and basic and diluted loss per common share is the same. In a profit year, under the treasury stock method, the weighted average number of common shares outstanding used for the calculation of diluted earnings per share assumes that the proceeds to be received on the exercise of dilutive stock options and warrants are used to repurchase common shares at the average price during the year.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
Basis of Presentation (Tables)	Apr. 30, 2023
Investments accounted for using equity method [abstract]
Summary of Subsidiaries which are Wholly Owned and Subject to Control	These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA US dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA US dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA US dollar Talem Therapeutics LLC ("Talem") 100 % USA US dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Apr. 30, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Classification and Measurement of Financial Assets and Liabilities	Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost
Schedule of Estimated Term of Asset	Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option
Summary of Amortization of Intangible Assets with Finite Lives	Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years

Acquisition of Biostrand (Table

Acquisition of Biostrand (Tables) - BioStrand B.V.	12 Months Ended
Acquisition of Biostrand (Tables) - BioStrand B.V.	Apr. 30, 2023
Disclosure of detailed information about business combination [line items]
Summary of Allocated Purchase Price	The Company has allocated the purchase price as follows: (in thousands) $ Cash 4,985 Common shares of the Company 29,126 Fair value of consideration 34,111 Cash 36 Amounts receivable 80 Unbilled revenue 8 Equipment and right-of-use assets 247 Intellectual property (not deductible for tax purposes) 28,459 Proprietary processes (not deductible for tax purposes) 391 Goodwill (not deductible for tax purposes) 12,658 Accounts payable and accrued liabilities assumed ( 342 ) Deferred revenue 9 Leases ( 223 ) Deferred income tax liability ( 7,212 ) 34,111
Summary of Changes in Value of Subsequent Payments	The changes in the value of the subsequent payments during the years ended April 30, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2021 — Amount at date of acquisition 1,317 Foreign exchange ( 12 ) Balance, April 30, 2022 1,305 Foreign exchange 45 Accretion 27 Working capital adjustment ( 68 ) Deferred acquisition payment ( 592 ) Balance, April 30, 2023 717 Less: Current portion ( 439 ) Non-current portion 278

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Apr. 30, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of Changes in the Value of Property and Equipment	The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Total Cost: Balance, April 30, 2021 96 36 49 2,730 94 353 5,048 — 8,406 Additions 39 3 — 311 1 — 991 138 1,483 Acquisition of BioStrand 24 — — 69 152 — — — 245 Disposals ( 21 ) ( 5 ) — — — — — — ( 26 ) Lease modification — — — ( 22 ) — — — — ( 22 ) Subsidy reimbursement — — — — — — ( 106 ) — ( 106 ) Asset impairment — — — ( 363 ) — — — — ( 363 ) Foreign exchange ( 2 ) 1 ( 2 ) ( 139 ) ( 8 ) — ( 261 ) — ( 411 ) Balance, April 30, 2022 136 35 47 2,586 239 353 5,672 138 9,206 Additions 138 — — 7,593 — 101 1,064 28 8,924 Completion of work-in-process — — — — — 166 — ( 166 ) — Disposals ( 3 ) — — ( 1,290 ) ( 95 ) — ( 700 ) — ( 2,088 ) Foreign exchange 17 18 3 196 23 6 437 — 700 Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 — 16,742 Accumulated Depreciation: Balance, April 30, 2021 61 28 42 1,334 27 296 2,594 — 4,382 Depreciation 31 6 7 698 23 51 940 — 1,756 Disposals ( 21 ) ( 5 ) — — — — — — ( 26 ) Asset impairment — — — ( 196 ) — — — — ( 196 ) Foreign exchange ( 1 ) — ( 2 ) ( 100 ) ( 4 ) 1 ( 163 ) — ( 269 ) Balance, April 30, 2022 70 29 47 1,736 46 348 3,371 — 5,647 Depreciation 84 3 — 1,109 58 40 977 — 2,271 Disposals ( 3 ) — — ( 1,274 ) ( 57 ) — ( 507 ) — ( 1,841 ) Foreign exchange 6 1 3 181 10 — 72 — 273 Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Net Book Value: April 30, 2022 66 6 — 850 193 5 2,301 138 3,559 April 30, 2023 131 20 — 7,333 110 238 2,560 — 10,392

Intangibles assets (Tables)

Intangibles assets (Tables)	12 Months Ended
Intangibles assets (Tables)	Apr. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Summary of Amortization for intangible assets with finite lives is provided over the following terms	Changes in the value of the intangible assets during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Internally Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2021 33 4,089 7,635 138 — 11,895 Costs expensed — — — — 191 191 Acquisition of BioStrand — 28,459 391 — — 28,850 Foreign exchange — ( 634 ) ( 667 ) ( 12 ) ( 11 ) ( 1,324 ) Balance, April 30, 2022 33 31,914 7,359 126 180 39,612 Foreign exchange — 3,229 744 13 18 4,004 Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Accumulated Amortization: Balance, April 30, 2021 1 1,445 4,391 — — 5,837 Amortization 7 398 1,577 — 31 2,013 Foreign exchange — ( 150 ) ( 477 ) — ( 1 ) ( 628 ) Balance, April 30, 2022 8 1,693 5,491 — 30 7,222 Amortization 7 2,710 1,477 128 92 4,414 Foreign exchange ( 1 ) 372 665 9 10 1,055 Balance, April 30, 2023 14 4,775 7,633 137 132 12,691 Net Book Value: April 30, 2022 25 30,221 1,868 126 150 32,390 April 30, 2023 19 30,368 470 2 66 30,925

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Apr. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Schedule of reconciliation of changes in goodwill	The goodwill was acquired as a result of the acquisitions of U-Protein, IPA Europe and, BioStrand. The changes in the value of goodwill during the year ended April 30, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2021 7,777 Foreign exchange ( 677 ) Acquisition of BioStrand 12,535 Balance, April 30, 2022 19,635 Foreign exchange 1,996 Asset impairment ( 2,460 ) Balance, April 30, 2023 19,171
Schedule of In Tabular Form Of Allocating Goodwill To Cash Generating Units	For annual impairment testing, goodwill is allocated to the following cash-generating units: (in thousands) April 30, April 30, Oss 3,109 2,823 Utrecht 4,710 4,277 BioStrand 11,352 12,535 19,171 19,635
Schedule of information for cash-generating units	The recoverable amount, growth rate assumptions and discount rates for each cash-generating unit as at April 30, 2023 and 2023 are as follows: Recoverable amount Terminal growth rates Discount rates (in thousands) 2023 2022 2023 2022 2023 2022 Oss 6,723 9,493 2.2 % 2.0 % 28.1 % 14.3 % Utrecht 11,405 12,483 2.2 % 2.0 % 24.1 % 14.3 % BioStrand 31,546 — 2.5 % — 33.1 % —

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
Convertible Debentures (Tables)	Apr. 30, 2023
Convertible Debentures [Abstract]
Summary of Changes in Value of New Debentures	The changes in the value of the New Debentures during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Liability Equity Balance, April 30, 2021 1,531 127 Accretion expense 85 — Conversion to shares ( 304 ) ( 24 ) Balance, April 30, 2022 1,312 103 Accretion expense 3 — Conversion to shares ( 1,315 ) ( 103 ) Balance, April 30, 2023 — —

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Apr. 30, 2023
Presentation of leases for lessee [abstract]
Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation	The following is a schedule of the Company’s future minimum lease payments related to the equipment and automobiles under finance lease and the office lease obligation: (in thousands) $ 2024 1,548 2025 1,033 2026 993 2027 989 2028 983 More than 5 years 3,849 Total minimum lease payments 9,395 Less: imputed interest ( 2,128 ) Total present value of minimum lease payments 7,267 Less: Current portion ( 1,116 ) Non-current portion 6,151
Summary of disclosure in tabular form of nature of companies leases	The nature of the Company’s leases by type of right-of-use asset as at April 30, 2023 is as follows: Right-of-use asset type No. of right-of-use assets leased Range of remaining term Average remaining lease term No. of leases with extension options No. of leases with options to purchase No. of leases with variable payments linked to an index No. of leases with termination options Lab and office facilities 4 0.5 - 9 years 3 years 4 — 3 2 Automobiles 6 1.5 - 4 years 2 years — — 6 6
Schedule of changes in the Value of the Right-of-Use Assets	The changes in the value of right-of-use assets during the years ended April 30, 2023 and 2022 are as follows: (in thousands) Building Automobile Lab Total Cost: Balance, April 30, 2021 2,730 94 623 3,447 Additions 311 1 — 312 Acquisition of BioStrand 69 152 — 221 Lease modification ( 22 ) — — ( 22 ) Loss on impairment ( 369 ) — — ( 369 ) Foreign exchange ( 133 ) ( 8 ) 28 ( 113 ) Balance, April 30, 2022 2,586 239 651 3,476 Additions 7,593 — — 7,593 Disposals ( 1,290 ) ( 95 ) ( 687 ) ( 2,072 ) Foreign exchange 196 23 36 255 Balance, April 30, 2023 9,085 167 — 9,252 Accumulated Depreciation: Balance, April 30, 2021 1,334 27 220 1,581 Depreciation 698 23 224 945 Loss on impairment ( 196 ) — — ( 196 ) Foreign exchange ( 100 ) ( 4 ) 16 ( 88 ) Balance, April 30, 2022 1,736 46 460 2,242 Depreciation 1,109 58 198 1,365 Disposals ( 1,274 ) ( 57 ) ( 507 ) ( 1,838 ) Foreign exchange 181 10 ( 151 ) 40 Balance, April 30, 2023 1,752 57 — 1,809 Net Book Value: April 30, 2022 850 193 191 1,234 April 30, 2023 7,333 110 — 7,443 Lease payments not recognized as a liability The Company has elected not to recognize a lease liability for leases with an expected term of 12 months or less. Additionally, certain variable lease payments are not permitted to be recognized as lease liabilities and are recognized in profit and loss as incurred. The expense relating to payments not included in the measurement of the lease liability during the years ended April 30, 2023 and 2022 are as follows: (in thousands) 2023 2022 Leases of low value assets 40 32 Variable lease payments 215 136 255 168

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
Share Capital (Tables)	Apr. 30, 2023
Disclosure of classes of share capital [abstract]
Summary of Stock Option Awards	The following table summarizes stock option awards during the years ended April 30, 2023 and 2022, including the fair value determined using the Black-Scholes option pricing model: Grant date Stock options granted Exercisable price/option Awarded to Share price on grant date Dividend yield Expected volatility Risk-free rate Expected life Fair value May 9, 2021 (3) 10,000 7.72 (7) Strategic Board Members 9.42 0 % 78 % 0.70 % 5.0 years $ 0.06 million June 13, 2021 (4) 43,750 7.14 (7) Consultant 8.63 0 % 78 % 0.71 % 3.0 years $ 0.2 million August 7, 2021 (2) 45,000 9.19 Employees 9.19 0 % 79 % 0.80 % 5.0 years $ 0.3 million January 2, 2022 (1) 28,250 6.89 Directors 6.89 0 % 77 % 1.18 % 4.0 years $ 0.1 million January 7, 2022 (2) 225,000 7.94 Officers and employees 7.94 0 % 77 % 1.42 % 5.0 years $ 1.1 million January 7, 2022 (2) 113,000 7.94 Employees 7.94 0 % 77 % 1.42 % 4.7 years $ 0.5 million January 13, 2022 (5) 15,000 8.30 Officer 8.30 0 % 77 % 1.43 % 1.0 years $ 0.04 million January 13, 2022 (2) 24,000 8.30 Employees 8.30 0 % 77 % 1.43 % 4.7 years $ 0.1 million March 11, 2022 (6) 25,000 6.35 Consultant 4.67 0 % 76 % 1.77 % 2.0 years $ 0.03 million May 15, 2022 (2) 80,000 5.79 Employees 3.79 0 % 77 % 2.73 % 5.0 years $ 0.3 million February 19, 2023 (1) 29,060 4.10 (7) Directors 4.10 (7) 0 % 77 % 3.57 % 4.0 years $ 0.1 million February 19, 2023 (2) 609,452 4.10 (7) Officers and employees 4.10 (7) 0 % 77 % 3.57 % 5.0 years $ 2.2 million (1) Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. (2) Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date . (3) Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date. (4) The option vested immediately. (5) Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. (6) Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date. (7) Priced in US dollars
Summary of Changes in Stock Option	The changes in the stock options for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 (outstanding) 1,358,900 7.93 3.11 Granted 529,000 7.98 — Exercised ( 188,000 ) 3.26 — Expired ( 60,250 ) 10.75 — Forfeited ( 15,500 ) 20.30 — Balance, April 30, 2022 (outstanding) 1,624,150 8.29 2.88 Granted 718,512 5.58 — Exercised ( 318,725 ) 3.27 — Expired ( 115,174 ) 9.35 — Forfeited ( 24,335 ) 9.45 — Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Unvested ( 813,845 ) 5.95 4.55 Exercisable, April 30, 2023 1,070,583 9.61 2.30
Summary of Options Outstanding	Details of the options outstanding as at April 30, 2023 are as follows: Expiry Date Exercise Remaining Options Unvested Exercisable September 24, 2023 4.75 0.40 19,000 - 19,000 November 7, 2023 4.10 0.52 20,000 - 20,000 December 31, 2023 5.00 0.67 180,000 - 180,000 January 11, 2024 5.00 0.70 60,000 - 60,000 September 1, 2025 8.50 2.34 250,000 - 250,000 January 6, 2026 20.30 2.69 210,000 - 210,000 May 9, 2026 (1) 10.46 3.03 10,000 6,667 3,333 January 2, 2026 6.89 2.68 28,250 - 28,250 January 7, 2027 7.94 3.69 332,666 110,000 222,666 January 7, 2027 8.30 3.71 31,000 5,333 25,667 February 22, 2024 6.35 0.82 25,000 - 25,000 May 15, 2027 5.79 4.04 80,000 53,333 26,667 February 19, 2027 (2) 5.55 3.81 29,060 29,060 - February 19, 2028 (2) 5.55 4.81 609,452 609,452 - 8.03 3.27 1,884,428 813,845 1,070,583 (1) Exercise price of US $ 7.72 . The figure in the table above is translated at the April 30, 2023 rate. (2) Exercise price of US $ 4.10 . The figure in the table above is translated at the April 30, 2023 rate.
Summary of Changes in Warrants	The changes in the warrants for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 878,300 3.50 0.90 Exercised ( 878,300 ) 3.50 — Balance, April 30, 2023 and 2022 — — —
Summary of Changes in Finder's Warrants	The changes in the finder’s warrants for the years ended April 30, 2023 and 2022 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2021 176,888 16.12 3.75 Exercised ( 46,777 ) 3.50 — Balance, April 30, 2022 130,111 21.59 3.77 Exercised — — — Balance, April 30, 2023 130,111 22.77 2.77
Details of Finder's Warrants Outstanding	Details of the finder’s warrants outstanding as at April 30, 2023 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 22.77 2.77 130,111 (1) Exercise price of US $ 16.81 . The figure in the table above is translated at the April 30, 2023 rate.

Employee Remuneration (Tables)

Employee Remuneration (Tables)	12 Months Ended
Employee Remuneration (Tables)	Apr. 30, 2023
Disclosure of employee benefits expenses [abstract]
Summary of Expenses Recognized for Employee Benefits	Expenses recognized for employee benefits for the years ended April 30, 2023 and 2022 are detailed below: (in thousands) 2023 2022 Wages, salaries 10,433 8,600 Employee benefits 926 798 Payroll taxes 939 714 Severance 194 8 Share-based payments 1,943 3,083 14,435 13,203

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Apr. 30, 2023
Related party transactions [abstract]
Schedule of Schedule of Compensation For Key Management	(in thousands) 2023 2022 Salaries and other short-term benefits 2,632 2,531 Severance (included in salaries) 183 8 Share-based payments 986 1,388 Director compensation (included in salaries) 335 355 4,136 4,282

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
Financial Instruments (Tables)	Apr. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
Schedule of Details of Amounts Receivable and Allowances for Doubtful Accounts	Details of amounts receivable and allowances for doubtful accounts as at April 30, 2023 and 2022 are as follows: (in thousands) 2023 2022 Amounts receivable 3,280 2,539 Allowance for doubtful accounts ( 33 ) ( 36 ) Amounts receivable, net 3,247 2,503
Summary of Classification and Measurement of Financial Assets and Liabilities	At April 30, 2023, the Company is exposed to currency risk through the following assets and liabilities denominated in US dollars and Euros: Euros US Dollars (in thousands) (€) (US $) Cash 2,465 2,193 Amounts receivable 1,236 679 Investment 82 — 3,783 2,872 Accounts payable and accrued liabilities ( 867 ) ( 1,700 ) Deferred acquisition payments ( 336 ) — Leases ( 664 ) ( 70 ) ( 1,867 ) ( 1,770 ) Net 1,916 1,102
Schedule of Contractual Cash Flow Requirements	Contractual cash flow requirements as at April 30, 2023 were as follows: < 1 1 - 2 2 - 5 >5 Total (in thousands) $ $ $ $ $ Accounts payable and accrued liabilities 3,386 — — — 3,386 Leases 1,548 1,033 2,965 3,849 9,395 Total 4,934 1,033 2,965 3,849 12,781

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Apr. 30, 2023
Classes of current inventories [abstract]
Summary of Detailed Information About Inventories	Inventories as at April 30, 2023 and 2022 consist of the following: (in thousands) 2023 2022 Supplies and parts 1,344 1,418 Antibodies 206 197 Work in process 510 — 2,060 1,615

Segmented Information and Eco_2

Segmented Information and Economic Dependence (Tables)	12 Months Ended
Segmented Information and Economic Dependence (Tables)	Apr. 30, 2023
Disclosure of operating segments [abstract]
Summary of Geographical Segments	The Company’s revenues are allocated to geographic regions for the year ended April 30, 2023 and 2022 as follows: Years ended (in thousands) 2023 2022 United States of America 9,365 6,816 Europe 9,450 9,429 Canada 618 572 Australia 630 1,540 Other 602 1,007 20,665 19,364 The Company’s non-current assets are allocated to geographic regions as of April 30, 2023 and 2022 as follows: April 30, April 30, North America - Corporate 89 76 North America 1,025 1,481 Belgium 40,406 41,355 Netherlands 19,501 13,265 61,021 56,177 Geographic segmentation of the Company’s net income (loss) for the year ended April 30, 2023 and 2022 is as follows: Years ended (in thousands) 2023 2022 North America - Corporate ( 8,422 ) ( 9,340 ) North America ( 12,601 ) ( 11,424 ) Belgium ( 7,024 ) ( 215 ) Netherlands 1,487 4,270 ( 26,560 ) ( 16,709 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the year ended April 30, 2023 and 2022 is as follows: Years ended Interest and accretion (in thousands) 2023 2022 North America - Corporate 39 258 North America 19 51 Belgium 20 3 Netherlands 318 107 396 419 Years ended Amortization and depreciation (in thousands) 2023 2022 North America - Corporate 14 56 North America 720 778 Belgium 2,543 — Netherlands 3,408 2,935 6,685 3,769
Summary of Revenues Allocated According to Revenue Types	The Company’s revenues are allocated according to revenue types for the year ended April 30, 2023 and 2022 as follows: Years ended (in thousands) 2023 2022 Project revenue 18,677 17,356 Product sales revenue 1,747 1,652 Cryostorage revenue 241 356 20,665 19,364

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
Supplemental Cash Flow Information (Tables)	Apr. 30, 2023
Statement of cash flows [abstract]
Summary of Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions (in thousands) April 30, April 30, Acquisition of building and equipment by lease 7,593 312 Settlement of convertible debentures 1,315 304 Fair value of shares issued pursuant to deferred acquisition payment to IPA Europe — 503
Summary of Changes in Liabilities Arose From Financing Activities	The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 1,237 ( 592 ) — — 27 ( 23 ) 649 Convertible debentures 1,312 — — ( 1,315 ) 3 — — Leases 1,455 ( 1,337 ) 7,593 — — ( 444 ) 7,267 Total 4,004 ( 1,929 ) 7,593 ( 1,315 ) 30 ( 467 ) 7,916 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign April 30, Deferred acquisition payments 498 — 1,248 ( 503 ) — ( 6 ) 1,237 Convertible debentures 1,531 — — ( 304 ) 85 — 1,312 Leases 1,926 ( 962 ) 533 — — ( 42 ) 1,455 Total 3,955 ( 962 ) 1,781 ( 807 ) 85 ( 48 ) 4,004

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Apr. 30, 2023
Disclosure Of Income Taxes [Abstract]
Summary of Differences and Related Tax Effects	Income tax expense differs from the amount that would be computed by applying the federal and provincial statutory tax rates of 27 % (2021 – 27 %) to the earnings before income taxes. The reasons for the differences and related tax effects are as follows: 2023 2022 $ $ Earnings (loss) before income taxes ( 27,752 ) ( 15,848 ) Income taxes (recovery) on earnings before income taxes, at above basic rate ( 7,493 ) ( 3,627 ) Increase (decrease) in taxes resulting from: Nondeductible expenses 8 322 Estimated SR&ED ITC ( 198 ) — Effects of tax rate change and foreign exchange 209 12 Deferred income tax asset recognized — ( 138 ) Tax rate difference by jurisdiction 948 ( 359 ) Tax benefits not recognized 4,885 4,651 Impairment loss 602 — Prior year tax assessments and adjustments ( 420 ) — Other 267 — Income taxes (recovery) ( 1,192 ) 861 2023 2022 $ $ Current income taxes ( 242 ) 1,390 Deferred income taxes (recovery) ( 950 ) ( 529 ) Income taxes (recovery) ( 1,192 ) 861
Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities	Temporary differences give rise to the following deferred income tax assets and liabilities: 2023 2022 $ $ Other tax pools 31 ( 20 ) Capital assets net of lease liabilities ( 61 ) 8 Inventory and intangible assets ( 7,631 ) ( 8,093 ) Recognized deferred income tax liabilities ( 7,661 ) ( 8,105 ) 2023 2022 $ $ Non-capital losses carried forward (expire from 2026 to 2039 ) 9,930 10,514 Other tax pools — 1,373 Capital losses carried forward 295 194 Capital assets net of lease liabilities 20 13 Financing costs 746 979 Less: unrecognized deferred income tax asset ( 10,991 ) ( 13,073 ) Unrecognized deferred income tax liabilities — —

Nature of Operations - Addition

Nature of Operations - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Nature Of Operations [Abstract]
Operating losses	$ 26,560	$ 16,709
Accumulated deficit	73,088	$ 46,528
Cash on hand	$ 8,400

Basis of Presentation - Summary

Basis of Presentation - Summary of Subsidiaries which are Wholly Owned and Subject to Control (Details)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
ImmunoPrecise Antibodies (Canada) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Canada) Ltd.
Equity Interest percentage	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Equity Interest percentage	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Antibodies (N.D.) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (N.D.) Ltd.
Equity Interest percentage	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Antibodies (MA) LLC
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (MA) LLC
Equity Interest percentage	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
Talem Therapeutics LLC ("Talem")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Talem Therapeutics LLC ("Talem")
Equity Interest percentage	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Netherlands B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Netherlands B.V.
Equity Interest percentage	100%	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Equity Interest percentage	100%	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
BioStrand B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioStrand B.V.
Equity Interest percentage	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
Idea Family B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Idea Family B.V.
Equity Interest percentage	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioKey B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioKey B.V.
Equity Interest percentage	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioClue B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioClue B.V.
Equity Interest percentage	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
ImmunoPrecise Antibodies (Quebec), Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Quebec), Ltd.
Equity Interest percentage	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
9438-9244 Quebec, Inc
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	9438-9244 Quebec, Inc.
Equity Interest percentage	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar

Significant Accounting Polici_4

Significant Accounting Policies - Summary of Classification and Measurement of Financial Assets and Liabilities (Details)	12 Months Ended
	Apr. 30, 2023
Cash
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	Amortized cost
Amounts Receivable
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	Amortized cost
Investment
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	FVTPL
Accounts Payable and Accrued Liabilities
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost
Convertible Debentures
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost
Deferred Acquisition Payments
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Estimated Term of Asset (Details)	12 Months Ended
	Apr. 30, 2023
Lab Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	5 years
Furniture and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	5 years
Computer Hardware
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	2 years
Building
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Remaining term of the property lease
Automobile
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Remaining term of the automobile lease
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Shorter of useful life and remaining term of the lease plus the first renewal option
Computer Software
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	1 year

Significant Accounting Polici_6

Significant Accounting Policies - Summary of Amortization of Intangible Assets with Finite Lives (Details)	12 Months Ended
	Apr. 30, 2023
Internally generated development costs
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	5 years
Intellectual property
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Intellectual property \| Bottom of range [member]
Disclosure of detailed information about intangible assets [line items]
Term	10 years
Intellectual property \| Top of range [member]
Disclosure of detailed information about intangible assets [line items]
Term	15 years
Proprietary processes
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	5 years
Certifications
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	1 year
Customer list
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	2 years

Significant Accounting Polici_7

Significant Accounting Policies - Additional Information (Details) $ in Millions	12 Months Ended
	Apr. 30, 2023 CAD ($)
Disclosure of detailed information about intangible assets [line items]
Impairment of long-lived assets, description	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately.
BioStrand
Disclosure of detailed information about intangible assets [line items]
Impairment loss	$ 2.5

Critical Accounting Estimates_2

Critical Accounting Estimates And Judgments - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	$ 19,171	$ 19,635
Oss
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	3,100
Utrecht
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	4,700
Biostrand
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	11,400
Goodwill impairment	$ 2,500

Acquisition of Biostrand - Addi

Acquisition of Biostrand - Additional Information (Detail) $ in Thousands, € in Millions			12 Months Ended
	Apr. 13, 2022 CAD ($) shares	Apr. 13, 2022 EUR (€)	Apr. 30, 2023 CAD ($)	Apr. 30, 2022 CAD ($) shares	Apr. 30, 2022 EUR (€)	Apr. 30, 2022 EUR (€) shares	Apr. 13, 2022 EUR (€) shares
Disclosure of detailed information about business combination [line items]
Net income (loss)			$ (26,560)	$ (16,709)
Amortization on the intangible assets			$ 4,414	2,013
BioStrand B.V. [Member]
Disclosure of detailed information about business combination [line items]
Cash paid at the time or acquisition	$ 3,700						€ 2.7
Transaction costs				700
Fair value of common shares issued	$ 29,126
Net income (loss)				200
Deferred cash payment				$ 100	€ 1
Intellectual property assets useful life				15 years	15 years
BioStrand B.V. [Member] \| Escrow Agreement [Member] \| Tranche One [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors				15%		15%
BioStrand B.V. [Member] \| Escrow Agreement [Member] \| Tranche Two [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors				20%		20%
BioStrand B.V. [Member] \| Escrow Agreement [Member] \| Tranche Three [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors				65%		65%
BioStrand B.V. [Member] \| Ninety Days [Member]
Disclosure of detailed information about business combination [line items]
Period of deferred cash payments	90 days	90 days
Deferred cash payment	$ 700	€ 0.5
BioStrand B.V. [Member] \| Three Years [Member]
Disclosure of detailed information about business combination [line items]
Period of deferred cash payments	3 years	3 years
Deferred cash payment	$ 600	€ 0.5
BioStrand B.V. [Member] \| Ordinary shares [member]
Disclosure of detailed information about business combination [line items]
Number of common shares issued \| shares	4,077,774			4,077,774		4,077,774	4,077,774
Fair value of common shares issued				$ 29,100		€ 21.3

Acquisition of Biostrand - Summ

Acquisition of Biostrand - Summary of Allocated Purchase Price (Detail) - BioStrand B.V. [Member] $ in Thousands	Apr. 13, 2022 CAD ($)
Disclosure of detailed information about business combination [line items]
Cash	$ 4,985
Common shares of the Company	29,126
Fair value of consideration	34,111
Cash	36
Amounts receivable	80
Unbilled revenue	8
Equipment and right-of-use assets	247
Intellectual property (not deductible for tax purposes)	28,459
Proprietary processes (not deductible for tax purposes)	391
Goodwill (not deductible for tax purposes)	12,658
Accounts payable and accrued liabilities assumed	(342)
Deferred revenue	9
Leases	(223)
Deferred income tax liability	(7,212)
Total net assets acquired and liabilities assumed	$ 34,111

Acquisition of Biostrand - Su_2

Acquisition of Biostrand - Summary of Changes in Value of Subsequent Payments (Detail) - BioStrand B.V. [Member] - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of detailed information about business combination [line items]
Beginning balance	$ 1,305	$ 0
Amount at date of acquisition		1,317
Foreign exchange	45	(12)
Accretion	27
Working capital adjustment	(68)
Deferred acquisition payment	(592)
Ending balance	717	$ 1,305
Less: Current portion	(439)
Non-current portion	$ 278

Property and Equipment - Summar

Property and Equipment - Summary of Changes in the Value of Property and Equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 3,559
Ending balance	10,392	$ 3,559
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	9,206	8,406
Additions	8,924	1,483
Acquisition of BioStrand		245
Disposals	(2,088)	(26)
Lease modification		(22)
Subsidy reimbursement		(106)
Asset impairment		(363)
Foreign exchange	700	(411)
Ending balance	16,742	9,206
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(5,647)	(4,382)
Depreciation	2,271	1,756
Disposals	1,841	26
Asset impairment		(196)
Foreign exchange	273	(269)
Ending balance	(6,350)	(5,647)
Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	3,559
Ending balance	10,392	3,559
Computer Hardware \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	136	96
Additions	138	39
Acquisition of BioStrand		24
Disposals	(3)	(21)
Foreign exchange	17	(2)
Ending balance	288	136
Computer Hardware \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(70)	(61)
Depreciation	84	31
Disposals	3	21
Foreign exchange	6	(1)
Ending balance	(157)	(70)
Computer Hardware \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	66
Ending balance	131	66
Furniture and Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	35	36
Additions		3
Disposals		(5)
Foreign exchange	18	1
Ending balance	53	35
Furniture and Equipment \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(29)	(28)
Depreciation	3	6
Disposals		5
Foreign exchange	1
Ending balance	(33)	(29)
Furniture and Equipment \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	6
Ending balance	20	6
Computer Software \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	47	49
Foreign exchange	3	(2)
Ending balance	50	47
Computer Software \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(47)	(42)
Depreciation		7
Foreign exchange	3	(2)
Ending balance	(50)	(47)
Building \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,586	2,730
Additions	7,593	311
Acquisition of BioStrand		69
Disposals	(1,290)
Lease modification		(22)
Asset impairment		(363)
Foreign exchange	196	(139)
Ending balance	9,085	2,586
Building \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(1,736)	(1,334)
Depreciation	1,109	698
Disposals	1,274
Asset impairment		(196)
Foreign exchange	181	(100)
Ending balance	(1,752)	(1,736)
Building \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	850
Ending balance	7,333	850
Automobile \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	239	94
Additions		1
Acquisition of BioStrand		152
Disposals	(95)
Foreign exchange	23	(8)
Ending balance	167	239
Automobile \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(46)	(27)
Depreciation	58	23
Disposals	57
Foreign exchange	10	(4)
Ending balance	(57)	(46)
Automobile \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	193
Ending balance	110	193
Leasehold Improvements \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	353	353
Additions	101
Completion of work-in-process	166
Foreign exchange	6
Ending balance	626	353
Leasehold Improvements \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(348)	(296)
Depreciation	40	51
Foreign exchange		1
Ending balance	(388)	(348)
Leasehold Improvements \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	5
Ending balance	238	5
Lab Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	5,672	5,048
Additions	1,064	991
Disposals	(700)
Subsidy reimbursement		(106)
Foreign exchange	437	(261)
Ending balance	6,473	5,672
Lab Equipment \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(3,371)	(2,594)
Depreciation	977	940
Disposals	507
Foreign exchange	72	(163)
Ending balance	(3,913)	(3,371)
Lab Equipment \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,301
Ending balance	2,560	2,301
WIP - Leasehold Improvements \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	138
Additions	28	138
Completion of work-in-process	(166)
Ending balance		138
WIP - Leasehold Improvements \| Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 138
Ending balance		$ 138

Intangibles Assets - Summary of

Intangibles Assets - Summary of Changes in the Value of the Intangible Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 32,390
Ending balance	30,925	$ 32,390
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	39,612	11,895
Costs expensed		191
Foreign exchange	4,004	(1,324)
Ending balance	43,616	39,612
Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization		28,850
Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,222	5,837
Amortization	4,414	2,013
Foreign exchange	1,055	(628)
Ending balance	12,691	7,222
Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	32,390
Ending balance	30,925	32,390
Internally Generated Development Costs \| Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	33	33
Costs expensed
Foreign exchange
Ending balance	33	33
Internally Generated Development Costs \| Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization
Internally Generated Development Costs \| Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8	1
Amortization	7	7
Foreign exchange	(1)
Ending balance	14	8
Internally Generated Development Costs \| Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	25
Ending balance		25
Intellectual Properties \| Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	31,914	4,089
Costs expensed
Foreign exchange	3,229	(634)
Ending balance	35,143	31,914
Intellectual Properties \| Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization		28,459
Intellectual Properties \| Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,693	1,445
Amortization	2,710	398
Foreign exchange	372	(150)
Ending balance	4,775	1,693
Intellectual Properties \| Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	30,221
Ending balance		30,221
Proprietary Processes \| Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,359	7,635
Costs expensed
Foreign exchange	744	(667)
Ending balance	8,103	7,359
Proprietary Processes \| Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization		391
Proprietary Processes \| Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	5,491	4,391
Amortization	1,477	1,577
Foreign exchange	665	(477)
Ending balance	7,633	5,491
Proprietary Processes \| Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,868
Ending balance		1,868
Certifications \| Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	126	138
Costs expensed
Foreign exchange	13	(12)
Ending balance	139	126
Certifications \| Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization
Certifications \| Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance
Amortization	128
Foreign exchange	9
Ending balance	137
Certifications \| Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	126
Ending balance	2	126
Customer List \| Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	180
Costs expensed		191
Foreign exchange	18	(11)
Ending balance	198	180
Customer List \| Cost \| BioStrand B.V. [Member]
Disclosure of detailed information about intangible assets [line items]
Amortization
Customer List \| Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	30
Amortization	92	31
Foreign exchange	10	(1)
Ending balance	132	30
Customer List \| Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	150
Ending balance		$ 150

Goodwill - Schedule of Reconcil

Goodwill - Schedule of Reconciliation of Changes in Goodwill Explanatory (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	$ 19,635
Goodwill	19,171	$ 19,635
U Protein IPA Europe And Bio strand [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	19,635	7,777
Foreign exchange	1,996	(677)
Acquisition of BioStrand		12,535
Asset impairment	(2,460)
Goodwill	$ 19,171	$ 19,635

Goodwill - Schedule of Tabular

Goodwill - Schedule of Tabular Form of Allocating Goodwill to Cash Generating Units (Details) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	$ 19,171	$ 19,635
Goodwill Including Preliminary Value	19,171	19,635
Oss [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	3,109	2,823
Utrecht [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	4,710	4,277
Bio strand [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	$ 11,352	$ 12,535

Goodwill - Schedule of Informat

Goodwill - Schedule of Information for Individual Asset or Cash generating Unit (Details) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Oss [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 6,723	$ 9,493
Terminal growth rates	2.20%	2%
Discount rates	28.10%	14.30%
Utrecht [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 11,405	$ 12,483
Terminal growth rates	2.20%	2%
Discount rates	24.10%	14.30%
Bio strand [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 31,546
Terminal growth rates	2.50%
Discount rates	33.10%

Goodwill - Additional Informati

Goodwill - Additional Information (Details) $ in Millions	12 Months Ended
Goodwill - Additional Information (Details) $ in Millions	Apr. 30, 2023 CAD ($)
Disclosure of detailed information about intangible assets [line items]
Term for calculating profit marging for cash generating units	3 years
BioStrand
Disclosure of detailed information about intangible assets [line items]
Impairment loss	$ 2.5

Convertible Debentures - Additi

Convertible Debentures - Additional Information (Details) $ in Thousands			12 Months Ended
	May 27, 2020 CAD ($)	May 15, 2020 CAD ($)	Apr. 30, 2023 CAD ($) shares	Apr. 30, 2021 CAD ($)
Convertible Debentures [Line Items]
Convertible debentures conversion price \| shares			4.25
Carrying value of new debentures			$ 2,400
Equity Component
Convertible Debentures [Line Items]
Transaction costs			$ 10
New Debentures
Convertible Debentures [Line Items]
Convertible debentures interest rate	10%	10%	10%
Proceeds from issue of convertible debentures	$ 40	$ 2,590		$ 2,600
Convertible debentures maturity date	May 22, 2022	May 15, 2022
Description of conversion of debt to equity			The Company may force convert the principal amount of the New Debentures at $4.25 per share if the average closing price is equal to or greater than $7.50 for 20 trading days.
Consulting fees			$ 80
Legal and filing fees			30
Transaction costs			100
New Debentures \| 10% Convertible Debentures
Convertible Debentures [Line Items]
Carrying value of equity			$ 200
New Debentures \| 10% Convertible Debentures \| Discounted Cash Flow
Convertible Debentures [Line Items]
Effective interest rate			15%

Convertible Debentures - Summar

Convertible Debentures - Summary of Changes in Value of New Debentures (Details) - CAD ($) $ in Thousands			12 Months Ended
	May 27, 2020	May 15, 2020	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Convertible Debentures [Line Items]
Conversion to shares			$ (1,315)	$ (304)
Equity Component
Convertible Debentures [Line Items]
Transaction costs			(10)
New Debentures
Convertible Debentures [Line Items]
Proceeds	$ 40	$ 2,590			$ 2,600
Transaction costs			(100)
New Debentures \| Liability Component
Convertible Debentures [Line Items]
Beginning balance			1,312,000	1,531,000
Accretion expense			3,000	85,000
Conversion to shares			(1,315,000)	(304,000)
Ending balance				1,312,000	1,531,000
New Debentures \| Equity Component
Convertible Debentures [Line Items]
Beginning balance			103,000	127,000
Conversion to shares			$ (103,000)	(24,000)
Ending balance				$ 103,000	$ 127,000

Leases - Additional Information

Leases - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Presentation of Leases for Lessee [Line Items]
Asset impairment		$ 200
Cash outflow for leases	$ 1,300	$ 1,000
Right-of-use assets	$ 7,443
Initial term of lease	5 years
Renewal option of additional term of lease	5 years
Utrecht
Presentation of Leases for Lessee [Line Items]
Right-of-use assets	$ 6,200

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation (Details) $ in Thousands	Apr. 30, 2023 CAD ($)
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 9,395
Less: imputed interest	(2,128)
Total present value of minimum lease payments	7,267
Less: Current portion	(1,116)
Non-current portion	6,151
2024
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	1,548
2025
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	1,033
2026
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	993
2027
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	989
2028
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	983
More than 5 years
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 3,849

Leases - Summary of Disclosure

Leases - Summary of Disclosure in Tabular Form of Nature of Companies Leases (Detail)	12 Months Ended
	Apr. 30, 2023
Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	4
No. of leases with extension options	4
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	3
No. of leases with termination options	2
Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	6
No. of leases with extension options	0
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	6
No. of leases with termination options	6
Weighted average \| Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	3 years
Weighted average \| Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	2 years
Bottom of Range \| Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	6 months
Bottom of Range \| Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	1 year 6 months
Top of Range \| Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	9 years
Top of Range \| Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	4 years

Leases - Schedule of Changes in

Leases - Schedule of Changes in the Value of the Right-of-Use Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	$ 7,443
Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	3,476	$ 3,447
Additions	7,593	312
Acquisition of BioStrand		221
Lease modification		(22)
Loss on impairment		(369)
Disposals	(2,072)
Foreign exchange	255	(113)
Ending balance	9,252	3,476
Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	2,242	1,581
Depreciation	1,365	945
Loss on impairment		(196)
Disposals	(1,838)
Foreign exchange	40	(88)
Ending balance	1,809	2,242
Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,234
Ending balance		1,234
Building
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	7,333
Building \| Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	2,586	2,730
Additions	7,593	311
Acquisition of BioStrand		69
Lease modification		(22)
Loss on impairment		(369)
Disposals	(1,290)
Foreign exchange	196	(133)
Ending balance	9,085	2,586
Building \| Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,736	1,334
Depreciation	1,109	698
Loss on impairment		(196)
Disposals	(1,274)
Foreign exchange	181	(100)
Ending balance	1,752	1,736
Building \| Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	850
Ending balance		850
Automobile
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	110
Automobile \| Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	239	94
Additions		1
Acquisition of BioStrand		152
Disposals	(95)
Foreign exchange	23	(8)
Ending balance	167	239
Automobile \| Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	46	27
Depreciation	58	23
Disposals	(57)
Foreign exchange	10	(4)
Ending balance	57	46
Automobile \| Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	193
Ending balance		193
Lab Equipment \| Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	651	623
Disposals	(687)
Foreign exchange	36	28
Ending balance		651
Lab Equipment \| Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	460	220
Depreciation	198	224
Disposals	(507)
Foreign exchange	(151)	16
Ending balance		460
Lab Equipment \| Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	$ 191
Ending balance		$ 191

Leases - Summary of Disclosur_2

Leases - Summary of Disclosure in Tabular Form Of Expenses Relating to Payments not included in the Measurement of Lease Liability (Detail) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Presentation of leases for lessee [abstract]
Leases of low value assets	$ 40	$ 32
Variable lease payments	215	136
Measurement of the lease liability	$ 255	$ 168

Share Capital - Additional Info

Share Capital - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Apr. 13, 2022	May 03, 2021	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise, shares			263,537	188,000
Number of options, Exercised			318,725	188,000
Shares issued pursuant to option exercise			$ (716)	$ (612)
Shares issued pursuant to warrant exercise, shares				925,076
Shares issued pursuant to warrant exercise				$ (3,238)
Share-based payments			1,943	3,083
Convertible Debentures [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Debt conversion principal debt amount				$ 300
IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares				41,488
Shares issued pursuant to deferred payment for acquisition				$ 503
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise			$ (1,493)	(1,013)
Shares issued pursuant to warrant exercise				(3,491)
Share Capital \| IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition				$ 503
Share Capital \| Common Shares
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise, shares			263,537	188,000
Total gross proceeds from exercise of stock options			$ 700	$ 600
Shares issued pursuant to option exercise			$ 800	$ 400
Weighted average share price			$ 4.50	$ 7.95
Shares issued pursuant to warrant exercise, shares				925,076
Total gross proceeds from exercise of warrants				$ 3,200
Shares issued pursuant to warrant exercise				$ (300)
Shares issued pursuant to conversion of convertible debentures, Number of Shares			309,877	75,292
Convertible debentures			$ 1,300	$ 300
Debt conversion principal debt amount			1,300
Share Capital \| Common Shares \| IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares		41,488
Shares issued pursuant to deferred payment for acquisition		$ 500
Share Capital \| Common Shares \| BioStrand [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares	4,077,774
Shares issued pursuant to deferred payment for acquisition	$ 29,100
Contributed Surplus
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise			$ 777	401
Shares issued pursuant to warrant exercise				$ 253

Share Capital - Summary of Stoc

Share Capital - Summary of Stock Option Awards (Details) - 12 months ended Apr. 30, 2023 $ / shares in Units, $ in Thousands		CAD ($) shares yr $ / shares	CAD ($) shares yr $ / shares
May 9, 2021 \| Strategic board members
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[1]	May 9, 2021	May 9, 2021
Stock options granted \| shares	[1]	10,000	10,000
Exercisable price/option	[1],[2]	$ 7.72
Awarded to	[1]	Strategic Board Members	Strategic Board Members
Share price on grant date	[1]		$ 9.42
Dividend yield	[1]	0%	0%
Expected volatility	[1]	78%	78%
Risk- free rate	[1]	0.70%	0.70%
Expected life \| yr	[1]	5	5
Fair value \| $	[1]	$ 60	$ 60
June 13, 2021 \| Consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[3]	June 13, 2021	June 13, 2021
Stock options granted \| shares	[3]	43,750	43,750
Exercisable price/option	[2],[3]	$ 7.14
Awarded to	[3]	Consultant	Consultant
Share price on grant date	[3]		$ 8.63
Dividend yield	[3]	0%	0%
Expected volatility	[3]	78%	78%
Risk- free rate	[3]	0.71%	0.71%
Expected life \| yr	[3]	3	3
Fair value \| $	[3]	$ 200	$ 200
August 7, 2021 \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	August 7, 2021	August 7, 2021
Stock options granted \| shares	[4]	45,000	45,000
Exercisable price/option	[4]		$ 9.19
Awarded to	[4]	Employees	Employees
Share price on grant date	[4]		$ 9.19
Dividend yield	[4]	0%	0%
Expected volatility	[4]	79%	79%
Risk- free rate	[4]	0.80%	0.80%
Expected life \| yr	[4]	5	5
Fair value \| $	[4]	$ 300	$ 300
January 2, 2022 \| Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[5]	January 2, 2022	January 2, 2022
Stock options granted \| shares	[5]	28,250	28,250
Exercisable price/option	[5]		$ 6.89
Awarded to	[5]	Directors	Directors
Share price on grant date	[5]		$ 6.89
Dividend yield	[5]	0%	0%
Expected volatility	[5]	77%	77%
Risk- free rate	[5]	1.18%	1.18%
Expected life \| yr	[5]	4	4
Fair value \| $	[5]	$ 100	$ 100
January 7, 2022 \| Officers and employee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	January 7, 2022	January 7, 2022
Stock options granted \| shares	[4]	225,000	225,000
Exercisable price/option	[4]		$ 7.94
Awarded to	[4]	Officers and employees	Officers and employees
Share price on grant date	[4]		$ 7.94
Dividend yield	[4]	0%	0%
Expected volatility	[4]	77%	77%
Risk- free rate	[4]	1.42%	1.42%
Expected life \| yr	[4]	5	5
Fair value \| $	[4]	$ 1,100	$ 1,100
January 7, 2022 \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	January 7, 2022	January 7, 2022
Stock options granted \| shares	[4]	113,000	113,000
Exercisable price/option	[4]		$ 7.94
Awarded to	[4]	Employees	Employees
Share price on grant date	[4]		$ 7.94
Dividend yield	[4]	0%	0%
Expected volatility	[4]	77%	77%
Risk- free rate	[4]	1.42%	1.42%
Expected life \| yr	[4]	4.7	4.7
Fair value \| $	[4]	$ 500	$ 500
January 13, 2022 \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	January 13, 2022	January 13, 2022
Stock options granted \| shares	[4]	24,000	24,000
Exercisable price/option	[4]		$ 8.30
Awarded to	[4]	Employees	Employees
Share price on grant date	[4]		$ 8.30
Dividend yield	[4]	0%	0%
Expected volatility	[4]	77%	77%
Risk- free rate	[4]	1.43%	1.43%
Expected life \| yr	[4]	4.7	4.7
Fair value \| $	[4]	$ 100	$ 100
January 13, 2022 \| Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	January 13, 2022	January 13, 2022
Stock options granted \| shares	[6]	15,000	15,000
Exercisable price/option	[6]		$ 8.30
Awarded to	[6]	Officer	Officer
Share price on grant date	[6]		$ 8.30
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	1.43%	1.43%
Expected life \| yr	[6]	1	1
Fair value \| $	[6]	$ 40	$ 40
March 11, 2022 \| Consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[7]	March 11, 2022	March 11, 2022
Stock options granted \| shares	[7]	25,000	25,000
Exercisable price/option	[7]		$ 6.35
Awarded to	[7]	Consultant	Consultant
Share price on grant date	[7]		$ 4.67
Dividend yield	[7]	0%	0%
Expected volatility	[7]	76%	76%
Risk- free rate	[7]	1.77%	1.77%
Expected life \| yr	[7]	2	2
Fair value \| $	[7]	$ 30	$ 30
May 15, 2022 \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	May 15, 2022	May 15, 2022
Stock options granted \| shares	[4]	80,000	80,000
Exercisable price/option	[4]		$ 5.79
Awarded to	[4]	Employees	Employees
Share price on grant date	[4]		$ 3.79
Dividend yield	[4]	0%	0%
Expected volatility	[4]	77%	77%
Risk- free rate	[4]	2.73%	2.73%
Expected life \| yr	[4]	5	5
Fair value \| $	[4]	$ 300	$ 300
February 19, 2023 \| Officers and employee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	February 19, 2023	February 19, 2023
Stock options granted \| shares	[4]	609,452	609,452
Exercisable price/option	[2],[4]	$ 4.10
Awarded to	[4]	Officers and employees	Officers and employees
Share price on grant date	[2],[4]	$ 4.10
Dividend yield	[4]	0%	0%
Expected volatility	[4]	77%	77%
Risk- free rate	[4]	3.57%	3.57%
Expected life \| yr	[4]	5	5
Fair value \| $	[4]	$ 2,200	$ 2,200
February 19, 2023 \| Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[5]	February 19, 2023	February 19, 2023
Stock options granted \| shares	[5]	29,060	29,060
Exercisable price/option	[2],[5]	$ 4.10
Awarded to	[5]	Directors	Directors
Share price on grant date	[2],[5]	$ 4.10
Dividend yield	[5]	0%	0%
Expected volatility	[5]	77%	77%
Risk- free rate	[5]	3.57%	3.57%
Expected life \| yr	[5]	4	4
Fair value \| $	[5]	$ 100	$ 100

[1] Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date. Priced in US dollars The option vested immediately. Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date . Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date.

Share Capital - Summary of St_2

Share Capital - Summary of Stock Option Awards (Parenthetical) (Details)	12 Months Ended
	Apr. 30, 2023
May 9, 2021 \| Strategic Board [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date.
June 13, 2021 \| Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	The option vested immediately.
August 7, 2021 \| Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 2, 2022 \| Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date.
January 7, 2022 \| Officers And Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 7, 2022 \| Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 13, 2022 \| Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 13, 2022 \| Officer [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date.
March 11, 2022 \| Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date.
May 15, 2022 \| Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date
February 19, 2023 \| Officers And Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date
February 19, 2023 \| Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date.

Share Capital - Summary of Chan

Share Capital - Summary of Changes in Stock Option (Details)	12 Months Ended
	Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares $ / shares	Apr. 30, 2021 shares $ / shares
Disclosure of classes of share capital [abstract]
Number of options, Outstanding, Beginning balance \| shares	1,624,150	1,358,900
Number of options, Granted \| shares	718,512	529,000
Number of options, Exercised \| shares	(318,725)	(188,000)
Number of option, Expired \| shares	(115,174)	(60,250)
Number of options, Forfeited \| shares	(24,335)	(15,500)
Number of options, Outstanding \| shares	1,884,428	1,624,150	1,358,900
Number of options, Unvested \| shares	(813,845)
Number of options, Exercisable \| shares	1,070,583
Weighted average exercise price outstanding, Beginning balance \| $ / shares	$ 8.29	$ 7.93
Weighted average exercise price, Granted \| $ / shares	5.58	7.98
Weighted average exercise price, Exercised \| $ / shares	3.27	3.26
Weighted average exercise price, Expired \| $ / shares	9.35	10.75
Weighted average exercise price, Forfeited \| $ / shares	9.45	20.30
Weighted average exercise price outstanding, Ending balance \| $ / shares	8.03	$ 8.29	$ 7.93
Weighted average exercise price, Unvested \| $ / shares	5.95
Weighted average exercise price, Exercisable \| $ / shares	$ 9.61
Weighted average life remaining (years)	3 years 3 months 7 days	2 years 10 months 17 days	3 years 1 month 9 days
Weighted average life remaining (years), Unvested	4 years 6 months 18 days
Weighted average life remaining (years), Exercisable	2 years 3 months 18 days

Share Capital - Summary of Opti

Share Capital - Summary of Options Outstanding (Details)		12 Months Ended
Share Capital - Summary of Options Outstanding (Details)		Apr. 30, 2023 shares $ / shares		Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares	Apr. 30, 2021 shares
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price \| $ / shares		$ 8.03
Remaining life (year)		3 years 3 months 7 days
Options outstanding		1,884,428		1,884,428	1,624,150	1,358,900
Unvested		813,845		813,845
Vested		1,070,583		1,070,583
Option Expiry Date September 24, 2023
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		September 24, 2023
Exercise price \| $ / shares		$ 4.75
Remaining life (year)		4 months 24 days
Options outstanding		19,000		19,000
Vested		19,000		19,000
Option Expiry Date November 7, 2023
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		November 7, 2023
Exercise price \| $ / shares		$ 4.10
Remaining life (year)		6 months 7 days
Options outstanding		20,000		20,000
Vested		20,000		20,000
Option Expiry Date December 31, 2023
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		December 31, 2023
Exercise price \| $ / shares		$ 5
Remaining life (year)		8 months 1 day
Options outstanding		180,000		180,000
Vested		180,000		180,000
Option Expiry Date January 11, 2024
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 11, 2024
Exercise price \| $ / shares		$ 5
Remaining life (year)		8 months 12 days
Options outstanding		60,000		60,000
Vested		60,000		60,000
Option Expiry Date September 1, 2025
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		September 1, 2025
Exercise price \| $ / shares		$ 8.50
Remaining life (year)		2 years 4 months 2 days
Options outstanding		250,000		250,000
Vested		250,000		250,000
Option Expiry Date January 6, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 6, 2026
Exercise price \| $ / shares		$ 20.30
Remaining life (year)		2 years 8 months 8 days
Options outstanding		210,000		210,000
Vested		210,000		210,000
Option Expiry Date May 9, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	May 9, 2026
Exercise price \| (per share)		$ 10.46	[1]	$ 7.72
Remaining life (year)	[1]	3 years 10 days
Options outstanding	[1]	10,000		10,000
Unvested	[1]	6,667		6,667
Vested	[1]	3,333		3,333
Option Expiry Date January 2, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 2, 2026
Exercise price \| $ / shares		$ 6.89
Remaining life (year)		2 years 8 months 4 days
Options outstanding		28,250		28,250
Vested		28,250		28,250
Option Expiry Date January 7, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 7, 2027
Exercise price \| $ / shares		$ 7.94
Remaining life (year)		3 years 8 months 8 days
Options outstanding		332,666		332,666
Unvested		110,000		110,000
Vested		222,666		222,666
Option Expiry Date January 7, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 7, 2027
Exercise price \| $ / shares		$ 8.30
Remaining life (year)		3 years 8 months 15 days
Options outstanding		31,000		31,000
Unvested		5,333		5,333
Vested		25,667		25,667
Option Expiry Date February 22, 2024
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		February 22, 2024
Exercise price \| $ / shares		$ 6.35
Remaining life (year)		9 months 25 days
Options outstanding		25,000		25,000
Vested		25,000		25,000
Option Expiry Date May 15, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		May 15, 2027
Exercise price \| $ / shares		$ 5.79
Remaining life (year)		4 years 14 days
Options outstanding		80,000		80,000
Unvested		53,333		53,333
Vested		26,667		26,667
Option Expiry Date February 19, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	February 19, 2027
Exercise price \| $ / shares	[2]	$ 5.55
Remaining life (year)	[2]	3 years 9 months 21 days
Options outstanding	[2]	29,060		29,060
Unvested	[2]	29,060		29,060
Option Expiry Date February 19, 2028
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	February 19, 2028
Exercise price \| $ / shares	[2]	$ 5.55
Remaining life (year)	[2]	4 years 9 months 21 days
Options outstanding	[2]	609,452		609,452
Unvested	[2]	609,452		609,452

[1] Exercise price of US $ 7.72 . The figure in the table above is translated at the April 30, 2023 rate. Exercise price of US $ 4.10 . The figure in the table above is translated at the April 30, 2023 rate.

Share Capital - Summary of Op_2

Share Capital - Summary of Options Outstanding (Parenthetical) (Details) - Apr. 30, 2023	$ / shares		$ / shares
Disclosure of classes of share capital [line items]
Exercise price	$ 8.03
Option Expiry Date May 9, 2026
Disclosure of classes of share capital [line items]
Exercise price \| (per share)	$ 10.46	[1]	$ 7.72
Option 14 and 15
Disclosure of classes of share capital [line items]
Exercise price			$ 4.10

[1] Exercise price of US $ 7.72 . The figure in the table above is translated at the April 30, 2023 rate.

Share Capital - Summary of Ch_2

Share Capital - Summary of Changes in Warrants and Finder's Warrants (Details)	12 Months Ended
	Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares $ / shares	Apr. 30, 2021 shares $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Balance, Number of warrants \| shares		878,300
Exercised, Number of warrants \| shares		(878,300)
Balance, Number of warrants \| shares			878,300
Balance, Weighted average exercise price \| $ / shares		$ 3.50
Exercised, Weighted average exercise price \| $ / shares		$ 3.50
Balance, Weighted average exercise price \| $ / shares			$ 3.50
Weighted average life remaining (years)			10 months 24 days
Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Balance, Number of warrants \| shares	130,111	176,888
Exercised, Number of warrants \| shares	0	(46,777)
Balance, Number of warrants \| shares	130,111	130,111	176,888
Balance, Weighted average exercise price \| $ / shares	$ 21.59	$ 16.12
Exercised, Weighted average exercise price \| $ / shares	0	3.50
Balance, Weighted average exercise price \| $ / shares	$ 22.77	$ 21.59	$ 16.12
Weighted average life remaining (years)	2 years 9 months 7 days	3 years 9 months 7 days	3 years 9 months

Share Capital - Details of Warr

Share Capital - Details of Warrants and Finder's Warrants Outstanding (Details)		12 Months Ended
		Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares	Apr. 30, 2021 shares
Disclosure Of Classes Of Share Capital [Line Items]
Warrants outstanding				878,300
Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Warrants outstanding		130,111	130,111	176,888
Range One \| Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	Feb. 03, 2026
Exercise price $ \| $ / shares	[1]	$ 22.77
Remaining life (year)	[1]	2 years 9 months 7 days
Warrants outstanding	[1]	130,111

[1] Exercise price of US $ 16.81 . The figure in the table above is translated at the April 30, 2023 rate.

Share Capital - Details of Wa_2

Share Capital - Details of Warrants and Finder's Warrants Outstanding (Parenthetical) (Details)	12 Months Ended
	Apr. 30, 2023 $ / shares
Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Warrant exercisable price	$ 16.81

Employee Remuneration - Summary

Employee Remuneration - Summary of Expenses Recognized for Employee Benefits (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of employee benefits expenses [abstract]
Wages, salaries	$ 10,433	$ 8,600
Employee benefits	926	798
Payroll taxes	939	714
Severance	194	8
Share-based payments	1,943	3,083
Total employee benefits expense	$ 14,435	$ 13,203

Related Party Transactions - Sc

Related Party Transactions - Schedule of Compensation For Key Management (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure of transactions between related parties [abstract]
Salaries and other short-term benefits	$ 2,632	$ 2,531
Severance (included in salaries)	183	8
Share-based payments	986	1,388
Director compensation (included in salaries)	335	355
Related party transaction, due from (to) related party	$ 4,136	$ 4,282

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Millions	Apr. 30, 2023	Apr. 30, 2022
Related party transactions [abstract]
Accounts payable due to related parties	$ 0.9
Accrued liabilities related parties current		$ 0.4

Capital Management - Additional

Capital Management - Additional Information (Details) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Disclosure of objectives, policies and processes for managing capital [line items]
Shareholders Equity	$ 57,803	$ 75,285	$ 56,924
Capital Management
Disclosure of objectives, policies and processes for managing capital [line items]
Shareholders Equity	$ 60,600

Financial Instruments - Additio

Financial Instruments - Additional Information (Details)	Apr. 30, 2023 CAD ($)
USD
Disclosure Of Financial Instruments [Line Items]
Foreign currency exchange rate	1.3548
Euro
Disclosure Of Financial Instruments [Line Items]
Foreign currency exchange rate	1.4933

Financial Instruments - Schedul

Financial Instruments - Schedule of Details of Amounts Receivable and Allowances for Doubtful Accounts (Details) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Allowances For Doubtful Accounts [Abstract]
Amounts receivable, gross	$ 3,280	$ 2,539
Allowance for doubtful accounts	(33)	(36)
Amounts receivable, net	$ 3,247	$ 2,503

Financial Instruments - Sched_2

Financial Instruments - Schedule of Assets and Liabilities (Details) € in Thousands, $ in Thousands, $ in Thousands	Apr. 30, 2023 CAD ($)	Apr. 30, 2023 EUR (€)	Apr. 30, 2023 USD ($)	Apr. 30, 2022 CAD ($)	Apr. 30, 2021 CAD ($)
Disclosure Of Financial Instruments [Line Items]
Cash	$ 8,366			$ 30,047	$ 41,838
Investment	115			142
Total assets	77,813			93,647
Liabilities	$ (20,010)			$ (18,362)
Currency Risk
Disclosure Of Financial Instruments [Line Items]
Cash		€ 2,465	$ 2,193
Amounts receivable		1,236	679
Investment \| €		82
Total assets		3,783	2,872
Accounts payable and accrued liabilities		(867)	(1,700)
Deferred acquisition payments \| €		(336)
Leases		(664)	(70)
Liabilities		(1,867)	(1,770)
Net		€ 1,916	$ 1,102

Financial Instruments - Sched_3

Financial Instruments - Schedule of Contractual Cash Flow Requirements (Details) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Financial Instruments [Line Items]
Total liabilities	$ 20,010	$ 18,362
Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	3,386
Leases	9,395
Total liabilities	12,781
Liquidity Risk \| Not Later Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	3,386
Leases	1,548
Total liabilities	4,934
Liquidity Risk \| Later Than One Year and Not Later Than Two Years
Disclosure Of Financial Instruments [Line Items]
Leases	1,033
Total liabilities	1,033
Liquidity Risk \| Later Than Two Years and Not Later Than Five Years
Disclosure Of Financial Instruments [Line Items]
Leases	2,965
Total liabilities	2,965
Liquidity Risk \| More than 5 years
Disclosure Of Financial Instruments [Line Items]
Leases	3,849
Total liabilities	$ 3,849

Inventories - Summary of Detail

Inventories - Summary of Detailed Information About Inventories (Detail) - CAD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Classes of current inventories [abstract]
Supplies and parts	$ 1,344	$ 1,418
Antibodies	206	197
Work in process	510
Inventories	$ 2,060	$ 1,615

Commitments - Additional Inform

Commitments - Additional Information (Details) € in Millions	12 Months Ended
	Apr. 30, 2023 EUR (€)
Commitments [Line Items]
Minimum contingent earnout payment	€ 12
BioStrand [Member]
Commitments [Line Items]
Percentage of contingent earnout payment based on EBITDA	20%
Unpaid commitment related to earnout	€ 12
Oss The Netherlands [Member]
Commitments [Line Items]
Lease term years	5 years
Lease commencement date	Jan. 01, 2024
Estimated annual cost of indexed for inflation	€ 0.5
Lease Optional Extension Period	5 years

Grant and Subsidy Income - Addi

Grant and Subsidy Income - Additional Information (Details) - EUR (€) € in Millions	3 Months Ended
	Jul. 31, 2022	May 31, 2022
Grant And Subsidy Income [Abstract]
Grant awarded		€ 0.5
Proceeds from grants	€ 0.2

Segmented Information and Eco_3

Segmented Information and Economic Dependence - Summary of Geographical Segments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 20,665	$ 19,364
Non-current assets	61,021	56,177
Net income (loss)	(26,560)	(16,709)
Interest and accretion	396	419
Amortization and depreciation	6,685	3,769
United States of America
Disclosure Of Geographical Areas [Line Items]
Revenues	9,365	6,816
Europe
Disclosure Of Geographical Areas [Line Items]
Revenues	9,450	9,429
Canada
Disclosure Of Geographical Areas [Line Items]
Revenues	618	572
Australia
Disclosure Of Geographical Areas [Line Items]
Revenues	630	1,540
North America
Disclosure Of Geographical Areas [Line Items]
Non-current assets	1,025	1,481
Net income (loss)	(12,601)	(11,424)
Interest and accretion	19	51
Amortization and depreciation	720	778
North America \| Corporate
Disclosure Of Geographical Areas [Line Items]
Non-current assets	89	76
Net income (loss)	(8,422)	(9,340)
Interest and accretion	39	258
Amortization and depreciation	14	56
Belgium
Disclosure Of Geographical Areas [Line Items]
Non-current assets	40,406	41,355
Net income (loss)	(7,024)	(215)
Interest and accretion	20	3
Amortization and depreciation	2,543	0
Netherlands
Disclosure Of Geographical Areas [Line Items]
Non-current assets	19,501	13,265
Net income (loss)	1,487	4,270
Interest and accretion	318	107
Amortization and depreciation	3,408	2,935
Other
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 602	$ 1,007

Segmented Information and Eco_4

Segmented Information and Economic Dependence - Summary of Revenues Allocated According to Revenue Types (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 20,665	$ 19,364
Project Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	18,677	17,356
Product Sales Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	1,747	1,652
Cryo Storage Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 241	$ 356

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Summary of Non-cash Investing and Financing Transactions (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Statements [Line Items]
Acquisition of building and equipment by lease	$ 7,593	$ 312
Settlement of convertible debentures	1,315	304
IPA Europe
Statements [Line Items]
Fair value of shares issued pursuant to deferred acquisition payment	$ 0	$ 503

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Changes in Liabilities Arose From Financing Activities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	$ 4,004	$ 3,955
Cash Flows	(1,929)	(962)
Non-cash changes, Acquisition	7,593	1,781
Non-cash changes, Debt forgiven/ Settlement/ Disposal	(1,315)	(807)
Non-cash changes, Accretion	30	85
Non-cash changes, Foreign exchange movements and change in estimates	(467)	(48)
Ending balance	7,916	4,004
Deferred Acquisition Payments
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	1,237	498
Cash Flows	(592)
Non-cash changes, Acquisition		1,248
Non-cash changes, Debt forgiven/ Settlement/ Disposal		(503)
Non-cash changes, Accretion	27
Non-cash changes, Foreign exchange movements and change in estimates	(23)	(6)
Ending balance	649	1,237
Convertible Debentures
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	1,312	1,531
Non-cash changes, Debt forgiven/ Settlement/ Disposal	(1,315)	(304)
Non-cash changes, Accretion	3	85
Ending balance		1,312
Leases
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	1,455	1,926
Cash Flows	(1,337)	(962)
Non-cash changes, Acquisition	7,593	533
Non-cash changes, Foreign exchange movements and change in estimates	(444)	(42)
Ending balance	$ 7,267	$ 1,455

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	12 Months Ended
Income Taxes - Additional Information (Details)	Apr. 30, 2023	Apr. 30, 2021
Disclosure Of Income Taxes [Abstract]
Applicable tax rate	27%	27%

Income Taxes - Summary of Diffe

Income Taxes - Summary of Differences and Related Tax Rate (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Income Taxes [Abstract]
Earnings (loss) before income taxes	$ (27,752)	$ (15,848)
Income taxes (recovery) on earnings before income taxes, at above basic rate	(7,493)	(3,627)
Nondeductible expenses	8	322
Estimated SR&ED ITC	(198)
Effects of tax rate change and foreign exchange	209	12
Deferred income tax asset recognized		(138)
Tax rate difference by jurisdiction	948	(359)
Tax benefits not recognized	4,885	4,651
Impairment loss	602
Prior year tax assessments and adjustments	(420)
Other	267
Income taxes (recovery)	(1,192)	861
Current income taxes	(242)	1,390
Deferred income taxes (recovery)	$ (950)	$ (529)

Income Taxes - Summary of Tempo

Income Taxes - Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Income Taxes [Abstract]
Other tax pools	$ 31	$ (20)
Capital assets net of lease liabilities	(61)	8
Inventory and intangible assets	(7,631)	(8,093)
Recognized deferred income tax liabilities	(7,661)	(8,105)
Non-capital losses carried forward (expire from 2026 to 2039)	9,930	10,514
Other tax pools		1,373
Capital losses carried forward	295	194
Capital assets net of lease liabilities	20	13
Financing costs	746	979
Less: unrecognized deffered income tax asset	$ (10,991)	$ (13,073)

Income Taxes - Summary of Tem_2

Income Taxes - Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities (Parenthetical) (Details)	12 Months Ended
	Apr. 30, 2023
Bottom of Range
Disclosure Of Income Taxes [Line Items]
Non capital loss carried forward expiration period	2026
Top of Range
Disclosure Of Income Taxes [Line Items]
Non capital loss carried forward expiration period	2039

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ in Millions	3 Months Ended
	Jul. 31, 2023 CAD ($)
Lease Agreement
Disclosure of non-adjusting events after reporting period [line items]
Estimated annual cost	$ 0.4